<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Oncology Dashboard</title>
<script src="https://cdn.jsdelivr.net/npm/chart.js@4.4.1/dist/chart.umd.min.js"></script>
<style>
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
    background: #0f172a; color: #e2e8f0;
    min-height: 100vh;
  }
  body.locked > *:not(#pin-gate) { display: none !important; }
  #pin-gate {
    position: fixed; inset: 0; z-index: 99999;
    background: #0f172a;
    display: flex; align-items: center; justify-content: center; flex-direction: column;
    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
  }
  #pin-gate.hidden { display: none; }
  #pin-gate h2 { color: #f1f5f9; font-size: 22px; margin-bottom: 8px; }
  #pin-gate p { color: #94a3b8; font-size: 14px; margin-bottom: 24px; }
  #pin-gate .pin-inputs { display: flex; gap: 10px; margin-bottom: 20px; }
  #pin-gate .pin-inputs input {
    width: 48px; height: 56px; text-align: center; font-size: 24px; font-weight: 700;
    background: #1e293b; border: 2px solid #334155; border-radius: 10px;
    color: #f1f5f9; outline: none; caret-color: #38bdf8;
  }
  #pin-gate .pin-inputs input:focus { border-color: #38bdf8; }
  #pin-gate .pin-error { color: #f87171; font-size: 13px; min-height: 20px; margin-bottom: 12px; }
  #pin-gate button {
    background: #38bdf8; color: #0f172a; border: none; padding: 10px 32px;
    border-radius: 8px; font-size: 15px; font-weight: 600; cursor: pointer;
  }
  #pin-gate button:hover { background: #7dd3fc; }
  .header {
    background: linear-gradient(135deg, #1e293b 0%, #0f172a 100%);
    border-bottom: 1px solid #334155;
    padding: 20px 32px;
    display: flex; align-items: center; justify-content: space-between;
  }
  .header h1 { font-size: 22px; font-weight: 700; color: #f1f5f9; }
  .header .subtitle { font-size: 13px; color: #94a3b8; margin-top: 4px; }
  .stats-bar {
    display: flex; gap: 24px; 
  }
  .stat-card {
    text-align: center; padding: 8px 20px;
    background: #1e293b; border-radius: 10px; border: 1px solid #334155;
  }
  .stat-card .num { font-size: 24px; font-weight: 700; color: #38bdf8; }
  .stat-card .label { font-size: 11px; color: #94a3b8; text-transform: uppercase; letter-spacing: 0.5px; }
  
  .filters {
    display: flex; gap: 12px; padding: 16px 32px; background: #1e293b;
    border-bottom: 1px solid #334155; flex-wrap: wrap; align-items: center;
    position: sticky; top: 0; z-index: 100;
  }
  .filters label { font-size: 12px; color: #94a3b8; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; }
  .filters select {
    background: #0f172a; color: #e2e8f0; border: 1px solid #475569;
    padding: 8px 12px; border-radius: 8px; font-size: 13px; cursor: pointer;
    min-width: 160px;
  }
  .filters select:hover { border-color: #38bdf8; }
  .filter-group { display: flex; flex-direction: column; gap: 4px; }
  .reset-btn {
    background: #334155; color: #e2e8f0; border: none; padding: 8px 16px;
    border-radius: 8px; cursor: pointer; font-size: 13px; margin-left: auto;
    transition: background 0.2s;
  }
  .reset-btn:hover { background: #475569; }

  .dashboard { padding: 24px 32px; }
  .grid { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }
  .grid-3 { display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 20px; margin-bottom: 20px; }
  .card {
    background: #1e293b; border-radius: 12px; border: 1px solid #334155;
    padding: 20px; position: relative;
  }
  .card h3 { font-size: 14px; color: #94a3b8; font-weight: 600; margin-bottom: 16px; text-transform: uppercase; letter-spacing: 0.5px; }
  .chart-container { position: relative; width: 100%; }
  .chart-container.h300 { height: 300px; }
  .chart-container.h350 { height: 350px; }
  .chart-container.h400 { height: 400px; }

  .table-card { grid-column: 1 / -1; }
  .data-table {
    width: 100%; border-collapse: collapse; font-size: 13px;
  }
  .data-table th {
    text-align: left; padding: 10px 12px; border-bottom: 2px solid #334155;
    color: #94a3b8; font-weight: 600; font-size: 11px; text-transform: uppercase;
    letter-spacing: 0.5px; cursor: pointer; user-select: none;
  }
  .data-table th:hover { color: #38bdf8; }
  .data-table td {
    padding: 8px 12px; border-bottom: 1px solid #1e293b;
    color: #cbd5e1; max-width: 200px; overflow: hidden; text-overflow: ellipsis; white-space: nowrap;
  }
  .data-table td a:hover { text-decoration: underline !important; }
  .data-table tr:hover td { background: #1e293b; color: #f1f5f9; }
  .data-table tbody tr:nth-child(even) td { background: rgba(30,41,59,0.5); }
  .stage-badge {
    display: inline-block; padding: 3px 8px; border-radius: 12px; font-size: 11px; font-weight: 600;
  }
  .stage-Preclinical { background: #312e81; color: #a5b4fc; }
  .stage-Phase-I { background: #064e3b; color: #6ee7b7; }
  .stage-Phase-II { background: #713f12; color: #fcd34d; }
  .stage-Phase-III { background: #7c2d12; color: #fdba74; }
  .stage-Phase-IV { background: #581c87; color: #d8b4fe; }
  .stage-Approved { background: #14532d; color: #4ade80; }
  .stage-Other { background: #334155; color: #94a3b8; }
  
  .count-badge { 
    position: absolute; top: 16px; right: 20px; 
    background: #334155; color: #38bdf8; padding: 4px 10px; border-radius: 12px;
    font-size: 12px; font-weight: 600;
  }
  .pagination { display: flex; gap: 8px; justify-content: center; margin-top: 12px; align-items: center; }
  .pagination button {
    background: #334155; color: #e2e8f0; border: none; padding: 6px 12px;
    border-radius: 6px; cursor: pointer; font-size: 12px;
  }
  .pagination button:hover { background: #475569; }
  .pagination button:disabled { opacity: 0.4; cursor: not-allowed; }
  .pagination span { font-size: 12px; color: #94a3b8; }

  /* Tabs */
  .tabs { display: flex; gap: 0; background: #0f172a; border-bottom: 2px solid #334155; padding: 0 32px; }
  .tab-btn {
    padding: 12px 28px; font-size: 14px; font-weight: 600; color: #64748b;
    background: transparent; border: none; cursor: pointer; position: relative;
    transition: color 0.2s;
  }
  .tab-btn:hover { color: #cbd5e1; }
  .tab-btn.active { color: #38bdf8; }
  .tab-btn.active::after {
    content: ''; position: absolute; bottom: -2px; left: 0; right: 0;
    height: 2px; background: #38bdf8;
  }
  .tab-content { display: none; }
  .tab-content.active { display: block; }

  /* Analytics tab styles */
  .analytics { padding: 24px 32px; }
  .analytics .section-title {
    font-size: 18px; font-weight: 700; color: #f1f5f9; margin: 28px 0 16px 0;
    padding-bottom: 8px; border-bottom: 1px solid #334155;
  }
  .analytics .section-title:first-child { margin-top: 0; }
  .summary-cards { display: grid; grid-template-columns: repeat(4, 1fr); gap: 16px; margin-bottom: 24px; }
  .summary-card {
    background: #1e293b; border-radius: 12px; border: 1px solid #334155;
    padding: 20px; text-align: center;
  }
  .summary-card .big { font-size: 36px; font-weight: 800; }
  .summary-card .big.green { color: #4ade80; }
  .summary-card .big.red { color: #f87171; }
  .summary-card .big.blue { color: #38bdf8; }
  .summary-card .big.yellow { color: #fbbf24; }
  .summary-card .desc { font-size: 12px; color: #94a3b8; margin-top: 4px; text-transform: uppercase; letter-spacing: 0.5px; }
  .insight-box {
    background: #1e293b; border-radius: 12px; border: 1px solid #334155;
    padding: 20px; margin-bottom: 20px;
  }
  .insight-box h4 { color: #38bdf8; font-size: 13px; text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 12px; }
  .insight-box ul { list-style: none; padding: 0; }
  .insight-box li { padding: 6px 0; color: #cbd5e1; font-size: 13px; border-bottom: 1px solid rgba(51,65,85,0.5); }
  .insight-box li:last-child { border-bottom: none; }
  .insight-box li .tag {
    display: inline-block; padding: 2px 8px; border-radius: 8px; font-size: 11px; font-weight: 600; margin-right: 6px;
  }
  .tag-high { background: #14532d; color: #4ade80; }
  .tag-mid { background: #713f12; color: #fcd34d; }
  .tag-low { background: #7f1d1d; color: #fca5a5; }
</style>
</head>
<body class="locked">

<div id="pin-gate">
  <h2>Oncology Dashboard</h2>
  <p>Enter your 6-digit access code</p>
  <div class="pin-inputs">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
    <input type="tel" maxlength="1" autocomplete="off" inputmode="numeric">
  </div>
  <div class="pin-error" id="pin-error"></div>
  <button id="pin-submit">Access Dashboard</button>
</div>

<script>
(function() {
  var hash = 'a0b1c2d3';
  async function sha256(str) {
    var buf = await crypto.subtle.digest('SHA-256', new TextEncoder().encode(str));
    return Array.from(new Uint8Array(buf)).map(function(b) { return b.toString(16).padStart(2, '0'); }).join('');
  }
  var inputs = document.querySelectorAll('#pin-gate .pin-inputs input');
  inputs.forEach(function(inp, i) {
    inp.addEventListener('input', function() {
      if (inp.value.length === 1 && i < inputs.length - 1) inputs[i + 1].focus();
    });
    inp.addEventListener('keydown', function(e) {
      if (e.key === 'Backspace' && !inp.value && i > 0) inputs[i - 1].focus();
      if (e.key === 'Enter') document.getElementById('pin-submit').click();
    });
  });
  inputs[0].focus();
  document.getElementById('pin-submit').addEventListener('click', async function() {
    var pin = Array.from(inputs).map(function(i) { return i.value; }).join('');
    if (pin.length < 6) { document.getElementById('pin-error').textContent = 'Please enter all 6 digits'; return; }
    var h = await sha256(pin);
    if (h === 'c5b389beb081fe1e43ae92e895deca086b4eed5cf9efc7b78eebbbc9dc75c3f0') {
      document.body.classList.remove('locked');
      document.getElementById('pin-gate').classList.add('hidden');
      sessionStorage.setItem('dashboard_auth', '1');
    } else {
      document.getElementById('pin-error').textContent = 'Incorrect code';
      inputs.forEach(function(i) { i.value = ''; });
      inputs[0].focus();
    }
  });
  if (sessionStorage.getItem('dashboard_auth') === '1') {
    document.body.classList.remove('locked');
    document.getElementById('pin-gate').classList.add('hidden');
  }
})();
</script>

<div class="header">
  <div>
    <h1>Oncology Dashboard</h1>
    <div class="subtitle">Interactive analysis of <span id="totalCount">519</span> pipeline entries</div>
  </div>
  <div class="stats-bar">
    <div class="stat-card"><div class="num" id="statDrugs">-</div><div class="label">Drugs</div></div>
    <div class="stat-card"><div class="num" id="statTumors">-</div><div class="label">Tumor Types</div></div>
    <div class="stat-card"><div class="num" id="statCompanies">-</div><div class="label">Companies</div></div>
    <div class="stat-card"><div class="num" id="statApproved">-</div><div class="label">Approved</div></div>
  </div>
</div>

<div class="tabs">
  <button class="tab-btn active" onclick="switchTab('pipeline')">Pipeline</button>
  <button class="tab-btn" onclick="switchTab('analytics')">CT.gov Analytics</button>
</div>

<div id="tab-pipeline" class="tab-content active">
<div class="filters">
  <div class="filter-group">
    <label>Tumor Type</label>
    <select id="filterTumor"><option value="">All</option></select>
  </div>
  <div class="filter-group">
    <label>Stage</label>
    <select id="filterStage"><option value="">All</option></select>
  </div>
  <div class="filter-group">
    <label>Line of Treatment</label>
    <select id="filterLine"><option value="">All</option></select>
  </div>
  <div class="filter-group">
    <label>Mechanism</label>
    <select id="filterMOA"><option value="">All</option></select>
  </div>
  <div class="filter-group">
    <label>Year Range</label>
    <select id="filterYear"><option value="">All</option></select>
  </div>
  <div class="filter-group">
    <label>Status</label>
    <select id="filterStatus">
      <option value="active" selected>Active Trials</option>
      <option value="">All</option>
      <option value="approved">Approved Only</option>
    </select>
  </div>
  <div class="filter-group">
    <label>Country</label>
    <select id="filterCountry">
      <option value="us" selected>US Trials</option>
      <option value="">All</option>
    </select>
  </div>
  <div class="filter-group">
    <label>CT.gov Link</label>
    <select id="filterCTgov">
      <option value="yes" selected>With NCT ID only</option>
      <option value="">All</option>
    </select>
  </div>
  <button class="reset-btn" onclick="resetFilters()">Reset Filters</button>
</div>

<div class="dashboard">
  <div class="grid">
    <div class="card">
      <h3>Development Stage Distribution</h3>
      <span class="count-badge" id="stageCount"></span>
      <div class="chart-container h300"><canvas id="stageChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Tumor Type Distribution</h3>
      <span class="count-badge" id="tumorCount"></span>
      <div class="chart-container h300"><canvas id="tumorChart"></canvas></div>
    </div>
  </div>
  <div class="grid">
    <div class="card">
      <h3>Pipeline Timeline (First Results by Year)</h3>
      <div class="chart-container h350"><canvas id="timelineChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Top 15 Mechanisms of Action</h3>
      <div class="chart-container h350"><canvas id="moaChart"></canvas></div>
    </div>
  </div>
  <div class="grid">
    <div class="card">
      <h3>Stage by Tumor Type (Heatmap)</h3>
      <div class="chart-container h400"><canvas id="heatmapChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Line of Treatment</h3>
      <div class="chart-container h400"><canvas id="lineChart"></canvas></div>
    </div>
  </div>
  <div class="grid">
    <div class="card table-card">
      <h3>Pipeline Data Table</h3>
      <span class="count-badge" id="tableCount"></span>
      <table class="data-table">
        <thead><tr>
          <th onclick="sortTable('name')">Drug Name</th>
          <th onclick="sortTable('tumor_raw')">Tumor</th>
          <th onclick="sortTable('stage')">Stage</th>
          <th onclick="sortTable('line')">Line</th>
          <th onclick="sortTable('moa_raw')">Mechanism</th>
          <th onclick="sortTable('company_us')">Company (US)</th>
          <th onclick="sortTable('results_date')">First Results</th>
          <th>CT.gov</th>
        </tr></thead>
        <tbody id="tableBody"></tbody>
      </table>
      <div class="pagination">
        <button onclick="changePage(-1)" id="prevBtn">Prev</button>
        <span id="pageInfo"></span>
        <button onclick="changePage(1)" id="nextBtn">Next</button>
      </div>
    </div>
  </div>
</div>
</div><!-- end tab-pipeline -->

<div id="tab-analytics" class="tab-content">
<div class="analytics">

  <div class="summary-cards">
    <div class="summary-card"><div class="big blue" id="aTotal">519</div><div class="desc">Total Entries</div></div>
    <div class="summary-card"><div class="big green" id="aFound">194</div><div class="desc">Linked to CT.gov</div></div>
    <div class="summary-card"><div class="big red" id="aNotFound">325</div><div class="desc">Not Found</div></div>
    <div class="summary-card"><div class="big yellow" id="aPct">37.4%</div><div class="desc">Match Rate</div></div>
  </div>

  <div class="section-title">CT.gov Coverage by Development Stage</div>
  <div class="grid">
    <div class="card">
      <h3>Match Rate by Stage</h3>
      <div class="chart-container h300"><canvas id="aStageChart"></canvas></div>
    </div>
    <div class="card">
      <h3>CT.gov Trial Status (found entries)</h3>
      <div class="chart-container h300"><canvas id="aCtStatusChart"></canvas></div>
    </div>
  </div>

  <div class="section-title">Coverage by Tumor Type & Year</div>
  <div class="grid">
    <div class="card">
      <h3>Match Rate by Tumor Type</h3>
      <div class="chart-container h350"><canvas id="aTumorChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Match Rate by Year (First Results)</h3>
      <div class="chart-container h350"><canvas id="aYearChart"></canvas></div>
    </div>
  </div>

  <div class="section-title">Coverage by Mechanism of Action & Line of Treatment</div>
  <div class="grid">
    <div class="card">
      <h3>Match Rate by Mechanism of Action (top 15)</h3>
      <div class="chart-container h400"><canvas id="aMoaChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Match Rate by Line of Treatment</h3>
      <div class="chart-container h300"><canvas id="aLineChart"></canvas></div>
    </div>
  </div>

  <div class="section-title">Drug Name Pattern Analysis</div>
  <div class="grid">
    <div class="card">
      <h3>Naming Patterns: Found vs Not Found</h3>
      <div class="chart-container h300"><canvas id="aNamingChart"></canvas></div>
    </div>
    <div class="card">
      <h3>Stage x Tumor Heatmap (% linked)</h3>
      <div class="chart-container h300"><canvas id="aHeatChart"></canvas></div>
    </div>
  </div>

  <div class="section-title">Analysis Summary</div>
  <div class="card" style="margin-bottom:20px;">
    <div style="font-size:14px;line-height:2;color:#cbd5e1;padding:4px 8px;">
      <p style="font-size:18px;font-weight:700;color:#f1f5f9;margin-bottom:16px;">Result: 194 out of 519 (37.4%) matched to ClinicalTrials.gov</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">1. Development Stage is the strongest predictor</p>
      <p>The further along the pipeline, the higher the chance of finding a match on CT.gov. <span style="color:#f87171">Preclinical</span> drugs match only <b>16%</b> of the time &mdash; they are simply too early to have registered trials. <span style="color:#fbbf24">Phase I</span> jumps to <b>40%</b>, <span style="color:#fbbf24">Phase II</span> is at <b>34%</b>, while <span style="color:#4ade80">Phase III&ndash;IV</span> reach <b>50&ndash;55%</b>, and <span style="color:#4ade80">Approved</span> drugs hit <b>56%</b>. This is logical: preclinical candidates often haven't been registered on CT.gov yet.</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">2. Drug naming pattern is a strong signal</p>
      <p>Drugs with <b>digits and special characters</b> in their names (internal lab codes like <code style="color:#fbbf24;background:#1e293b;padding:2px 6px;border-radius:4px;">SC-CAR/CAR-16.21</code>, <code style="color:#fbbf24;background:#1e293b;padding:2px 6px;border-radius:4px;">FGF14 CART</code>) are found <b>less often</b> (29% vs 38%). Conversely, drugs with <b>INN-standard names</b> (endings like <code style="color:#4ade80;background:#1e293b;padding:2px 6px;border-radius:4px;">-mab</code>, <code style="color:#4ade80;background:#1e293b;padding:2px 6px;border-radius:4px;">-nib</code>, <code style="color:#4ade80;background:#1e293b;padding:2px 6px;border-radius:4px;">-lib</code>) match <b>more often</b> (30% vs 24%). This means: many of the unmatched entries are <b>internal laboratory codes</b> that aren't publicly registered.</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">3. Mechanism of Action shows clear differences</p>
      <p><span style="color:#4ade80"><b>100%</b> matched: Natural Killer Cells</span>. Also high: <b>NK cells</b> (83%), <b>Cancer vaccines</b> (71%), <b>Anti-PD-1 mAb</b> (67%), <b>HDAC inhibitors</b> (63%). On the other end: <span style="color:#f87171"><b>ODC inhibitors</b> &mdash; 0% (all 7 not found)</span>, and <b>Radiopharmaceuticals</b> at only 13%. Well-established, widely-studied mechanisms link to CT.gov far better than novel experimental ones.</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">4. Year of first results shows a moderate trend</p>
      <p>Older drugs (<b>2006&ndash;2014</b>) have a higher match rate of <b>~55%</b> &mdash; their trials have been published and indexed for years. The <b>2022&ndash;2027</b> range stabilizes around <b>34%</b> with many early-stage experimental compounds. Beyond <b>2028</b>, the rate drops to <b>28%</b> &mdash; these are future projections for drugs still in early development.</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">5. Line of Therapy</p>
      <p><b>Preclinical</b> line matches at only <b>18%</b> (not yet on CT.gov). <b>Neoadjuvant</b> hits <b>100%</b> (though only 3 entries). The bulk &mdash; <b>Second line</b> (400 entries) &mdash; matches at <b>39%</b>. <b>First line</b> does better at <b>46%</b>.</p>

      <p style="font-size:15px;font-weight:700;color:#38bdf8;margin:20px 0 10px;">6. Companies show no clear pattern</p>
      <p>Large pharma (Novartis, Bayer) range <b>40&ndash;75%</b>. Academic centres vary widely from 0% to 71%. Company alone is not a reliable predictor of CT.gov match.</p>

      <div style="background:#0f172a;border-radius:10px;padding:20px;margin-top:24px;border:1px solid #334155;">
        <p style="font-size:16px;font-weight:700;color:#f1f5f9;margin-bottom:12px;">Conclusion</p>
        <p>The main reason 63% of entries are not found is <b>not a search error, but the nature of the data</b>. The ~325 unmatched records are predominantly:</p>
        <ul style="margin:12px 0 0 20px;list-style:disc;">
          <li style="padding:4px 0;"><b>Experimental drugs with internal codes</b> (lab designations that don't exist on CT.gov)</li>
          <li style="padding:4px 0;"><b>Early preclinical candidates</b> not yet registered for clinical trials</li>
          <li style="padding:4px 0;"><b>Future-dated drugs (2028&ndash;2033)</b> that haven't entered clinical trials yet</li>
        </ul>
        <p style="margin-top:12px;color:#94a3b8;font-style:italic;">This is not a bug &mdash; it reflects reality: not all drugs in a pipeline have registered clinical trials yet.</p>
      </div>
    </div>
  </div>

</div>
</div><!-- end tab-analytics -->

<script>
const RAW_DATA = [{"name": "Abiraterone", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Chla Tai", "company_eu": "EU: Chla Tai", "line": "Solid tumors", "stage": "Phase II", "year": 2029.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "RTK/VEGFR inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2029", "nct_id": "NCT03298087", "ct_url": "https://clinicaltrials.gov/study/NCT03298087", "ct_title": "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer", "ct_status": "COMPLETED"}, {"name": "SC-CAR/CAR-16.21 CART", "tumor": "Solid tumors", "company_us": "US: Seattle Children's", "company_eu": "EU: Seattle Children's", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "GPC3 CAR-T (IL-15BL21-armored, iCargo9 switch)", "stage_raw": "Phase I", "results_date": "Aug 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "B7-H3 CAR-T Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Jade", "company_eu": "EU: Jade", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "CART B7-H3", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Nov 2030", "nct_id": "NCT07222735", "ct_url": "https://clinicaltrials.gov/study/NCT07222735", "ct_title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "B7-H3 CAR-T Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Chla Tai", "company_eu": "EU: Chla Tai", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "RTK/VEGFR inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2030", "nct_id": "NCT07222735", "ct_url": "https://clinicaltrials.gov/study/NCT07222735", "ct_title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "CAR-CG4, 16-21", "tumor": "Solid tumors", "company_us": "US: Childrens Children's", "company_eu": "EU: Seattle Children's", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "GPC3 CAR-T (IL-15BL21-armored, iCargo9 switch)", "stage_raw": "Phase I", "results_date": "Apr 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pafurasib (bemaritide)", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Daechi Daejeo", "company_eu": "EU: Daechi Daejeo", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-HER-3 ADC: monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GPG1+ORNA Vaccine", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Chinese Pharmaceuticals (China)", "company_eu": "EU: Chinese Pharmaceuticals (China)", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "mRNA vaccine", "stage_raw": "Early Phase I", "results_date": "May 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "FGF14 CART", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Longling Technology", "company_eu": "EU: Longling Technology", "line": "Solid tumors", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "CART FGF14", "stage_raw": "Phase I", "results_date": "Dec 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Panabiota", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Novavax", "company_eu": "EU: Novavax", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGF13 inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Panasilib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Nevavax", "company_eu": "EU: Nevavax", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "PEEL-224 Candidate", "tumor": "Solid tumors", "company_us": "US: PEEL Therapeutics", "company_eu": "EU: PEEL Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2028", "nct_id": "NCT06709495", "ct_url": "https://clinicaltrials.gov/study/NCT06709495", "ct_title": "Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "Imatinib/nib", "tumor": "Solid tumors", "company_us": "US: Summit Therapeutics", "company_eu": "EU: Summit Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD; LVEDF hepatic monoclonal antibody", "stage_raw": "Phase II", "results_date": "Nov 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Intratuberosib beta Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Hemotech", "company_eu": "EU: Hemotech", "line": "Third line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-IGF-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Sep 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Intratuberosib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Summit Therapeutics", "company_eu": "EU: Summit Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-PD; LVEDF hepatic monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Libacitinib", "tumor": "Solid tumors", "company_us": "US: Invevac Therapeutics", "company_eu": "EU: Invevac Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Tumor infiltrating lymphocytes", "stage_raw": "Phase I", "results_date": "Jul 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Sikimarivib", "tumor": "Solid tumors", "company_us": "US: Sentient Medicinals", "company_eu": "EU: Sentient Medicinals", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CHK2 inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Paclitaxel/ab", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Leuki Pharmaceuticals", "company_eu": "EU: Leuki Pharmaceuticals", "line": "Neoadjuvant Only", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-FGF-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Mar 2025", "nct_id": "NCT02158520", "ct_url": "https://clinicaltrials.gov/study/NCT02158520", "ct_title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery", "ct_status": "COMPLETED"}, {"name": "TTI-lexibotinoide", "tumor": "Solid tumors", "company_us": "US: ITM Oncology", "company_eu": "EU: ITM Oncology", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-ISIT2 radioisocyanography", "stage_raw": "Phase I", "results_date": "Jan 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "MAAC-1.1", "tumor": "Other", "company_us": "US: HEY2 Biotech", "company_eu": "EU: HEY2 Biotech", "line": "First line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue", "moa_raw": "Dendritic Cell Vaccine", "stage_raw": "Phase II", "results_date": "Feb 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CARE T cells", "tumor": "Solid tumors", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "IL-15IL-21-armored GPC3 CART", "stage_raw": "Phase I", "results_date": "Feb 2028", "nct_id": "NCT04462406", "ct_url": "https://clinicaltrials.gov/study/NCT04462406", "ct_title": "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "MAC", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Hospira Hospital", "company_eu": "EU: Hospira Hospital", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Cancer vaccine", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Jun 2027", "nct_id": "NCT02996773", "ct_url": "https://clinicaltrials.gov/study/NCT02996773", "ct_title": "Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine", "ct_status": "COMPLETED"}, {"name": "Forkatopalib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Likasha Technology", "company_eu": "EU: Likasha Technology", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "PARP inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "PARP inhibitor", "stage_raw": "Phase II", "results_date": "Aug 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TIL", "tumor": "Solid tumors", "company_us": "US: Sloan/Ackley/Jaxxis", "company_eu": "EU: Sloan/Ackley/Jaxxis", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Tumor infiltrating lymphocytes", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT00045149", "ct_url": "https://clinicaltrials.gov/study/NCT00045149", "ct_title": "Biological Therapy in Treating Patients With Metastatic Melanoma", "ct_status": "COMPLETED"}, {"name": "Imrecoxitinib NID (10)", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Serven", "company_eu": "EU: Serven", "line": "First line", "stage": "Phase II", "year": 2024.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eribulin", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Esai", "company_eu": "EU: Esai", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Microtubule inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT03441360", "ct_url": "https://clinicaltrials.gov/study/NCT03441360", "ct_title": "Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)", "ct_status": "COMPLETED"}, {"name": "Vialuroloninib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: AbdAmerica", "company_eu": "EU: AbdAmerica", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-IGF-1a LCZLA-4 Bispecific", "stage_raw": "Phase I", "results_date": "Sep 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Abroliziomab", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Chla Tai", "company_eu": "EU: Chla Tai", "line": "Second line", "stage": "Phase IV", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "RTK/VEGFR inhibitor", "stage_raw": "Phase IV", "results_date": "Dec 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TFRD Expansion IND Case", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Childrens Research", "company_eu": "EU: Medicaelous", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Allogeneic TCR-g-NK cells", "stage_raw": "Phase II", "results_date": "Nov 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Olaparib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Chla Tai", "company_eu": "EU: Chla Tai", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "CART HER2", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "TFRD Expanded INI Case", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Childrens Research", "company_eu": "EU: Medicaelous", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Allogeneic TCR-g-NK cells", "stage_raw": "Phase II", "results_date": "Nov 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CART HER2", "tumor": "Other", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "User cancer HCC", "moa_raw": "CART GPC3", "stage_raw": "Phase I", "results_date": "Jan 2026", "nct_id": "NCT04433221", "ct_url": "https://clinicaltrials.gov/study/NCT04433221", "ct_title": "Combination Immunotherapy Targeting Sarcomas", "ct_status": "UNKNOWN"}, {"name": "Ginetinib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Medicinos", "company_eu": "EU: Medicinos", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGF13 FGF13 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CART HER2 Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase II", "year": 2006.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "IL-15IL-21-armored GPC3 CART", "stage_raw": "Phase II", "results_date": "Aug 2006", "nct_id": "NCT04433221", "ct_url": "https://clinicaltrials.gov/study/NCT04433221", "ct_title": "Combination Immunotherapy Targeting Sarcomas", "ct_status": "UNKNOWN"}, {"name": "Oncolabimab plus Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Ilem Pharmaceutical", "company_eu": "EU: Ilem Pharmaceutical", "line": "First line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "L-19TNF-aI fusion protein", "stage_raw": "Phase II", "results_date": "Nov 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Papragulosib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Bayer", "company_eu": "EU: Bayer", "line": "First line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "MIT inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Combotrelbib Combination", "tumor": "Other", "company_us": "US: Luophaia Ichkinology", "company_eu": "EU: Luophaia Ichkinology", "line": "First line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Lung cancer NSCLC", "moa_raw": "Anti-IGF-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ataluren Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Ataluren", "company_eu": "EU: Ataluren", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-PD-L1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jan 2027", "nct_id": "NCT01557400", "ct_url": "https://clinicaltrials.gov/study/NCT01557400", "ct_title": "Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada", "ct_status": "COMPLETED"}, {"name": "Ginetinib plus Combination", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Medicinos", "company_eu": "EU: Medicinos", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Anti-PD-L1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jan 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nilothrib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Takeda", "company_eu": "EU: Takeda", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "PARP inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "PARP inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "SCI-CART-H3", "tumor": "Solid tumors", "company_us": "US: Seattle Children's", "company_eu": "EU: Seattle Children's", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "CART B7-H3", "tumor_raw": "Solid tumors", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "SO-TA", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Highlight Therapeutics", "company_eu": "EU: Highlight Therapeutics", "line": "First line", "stage": "Phase I", "year": 2026.0, "moa": "Cancer vaccine", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "Jan 2026", "nct_id": "NCT04384003", "ct_url": "https://clinicaltrials.gov/study/NCT04384003", "ct_title": "Integrated Exercise Therapy Interventions on the Performance and Injury Prevention in Competitive Sports", "ct_status": "UNKNOWN"}, {"name": "GPC3-CART", "tumor": "Solid tumors", "company_us": "US: Childrens Research", "company_eu": "EU: Medicaelous", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART GPC3", "stage_raw": "Phase I", "results_date": "Aug 2024", "nct_id": "NCT06084884", "ct_url": "https://clinicaltrials.gov/study/NCT06084884", "ct_title": "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "GPC3 CART", "tumor": "Solid tumors", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART GPC3", "stage_raw": "Phase I", "results_date": "Aug 2024", "nct_id": "NCT06084884", "ct_url": "https://clinicaltrials.gov/study/NCT06084884", "ct_title": "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Ora Medically Candidates", "tumor": "Solid tumors", "company_us": "US: Edixon Oncodevice", "company_eu": "EU: Edixon Oncodevice", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase I", "results_date": "Apr 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Sigatetinib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Eli Lily", "company_eu": "EU: Eli Lily", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "RET inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mervemitinib", "tumor": "Soft tumors", "company_us": "US: Merck", "company_eu": "EU: Merck", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tumors", "moa_raw": "HCMC inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tepinib", "tumor": "Soft tumors", "company_us": "US: Kura Oncology", "company_eu": "EU: Kura Oncology", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tumors", "moa_raw": "Farnesyl transferase inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Alotremiteinib", "tumor": "Soft tumors", "company_us": "US: Eli Lily", "company_eu": "EU: Eli Lily", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tumors", "moa_raw": "CDK6 inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Colubamitinib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Genentech", "company_eu": "EU: Starhez", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "MEK inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Iohidominib", "tumor": "Solid tumors", "company_us": "US: Serven", "company_eu": "EU: Serven", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "IGFII inhibitor", "stage_raw": "Phase I", "results_date": "Mar 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pricamisib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Aravax Therapeutics", "company_eu": "EU: Aravax Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "OHC 1/2 inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Staurosisab", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Esisoe Therapeutics", "company_eu": "EU: Esisoe Therapeutics", "line": "First line", "stage": "Phase II", "year": 2020.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Wimachib", "tumor": "Solid tumors", "company_us": "US: Adeve", "company_eu": "EU: Adeve", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "PCLL2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mabexakib", "tumor": "Solid tumors", "company_us": "US: Baxis", "company_eu": "EU: Baxis", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "PCLL2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Riviceccib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Exisox Therapeutics", "company_eu": "EU: Exisox Therapeutics", "line": "First line", "stage": "Phase II", "year": 2020.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Vinafinicib", "tumor": "Soft tumors", "company_us": "US: Adove", "company_eu": "EU: Adove", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tumors", "moa_raw": "PCL2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Afatinib", "tumor": "Other", "company_us": "US: Plusk", "company_eu": "EU: Plusk", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue Combination", "moa_raw": "CDK6 inhibitor", "stage_raw": "Phase I", "results_date": "Aug 2024", "nct_id": "NCT01396265", "ct_url": "https://clinicaltrials.gov/study/NCT01396265", "ct_title": "Drug Interaction Study With Rifampicin and Afatinib", "ct_status": "COMPLETED"}, {"name": "Ubertinib", "tumor": "Soft tumors", "company_us": "US: Valley Therapharm", "company_eu": "EU: Valley Therapharm", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Soft tumors", "moa_raw": "ERK inhibitor", "stage_raw": "Phase I", "results_date": "Mar 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CTL-GG2 CART", "tumor": "Other", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "CNS Neuroblastoma", "moa_raw": "CART CTL-GG2", "stage_raw": "Phase I", "results_date": "May 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ECP-Encitinib", "tumor": "Solid tumors", "company_us": "US: Childrens Research", "company_eu": "EU: Seattle Childrens", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART ECP/HCCD19", "stage_raw": "Phase I", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pabicisib", "tumor": "Solid tumors", "company_us": "US: Eli Lily", "company_eu": "EU: Eli Lily", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CDK6 inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Vepholinib (1.1)", "tumor": "Solid tumors", "company_us": "US: Celestial", "company_eu": "EU: Celestial", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Radiopharmaceutical", "tumor_raw": "Solid tumors", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Calisan", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Esai", "company_eu": "EU: Esai", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "Microtubule inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2021", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BAL-110", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Biompharm", "company_eu": "EU: Biompharm", "line": "First line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "STAT3 inhibitor-TK adaptor", "stage_raw": "Phase II", "results_date": "Dec 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Revincib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Exisox Therapeutics", "company_eu": "EU: Exisox Therapeutics", "line": "First line", "stage": "Phase II", "year": 2020.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Isoptinib (1.1)", "tumor": "Solid tumors", "company_us": "US: Celestial Medicines", "company_eu": "EU: Celestial Medicines", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Radiopharmaceutical", "tumor_raw": "Solid tumors", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Gifinib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Esai", "company_eu": "EU: Esai", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "Alkylating agent", "stage_raw": "Phase II", "results_date": "Oct 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lenimavib", "tumor": "Soft tissue sarcoma (STD)", "company_us": "US: Takeda", "company_eu": "EU: Takeda", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Soft tissue sarcoma (STD)", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Encorafenib", "tumor": "Solid tumors", "company_us": "US: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-BRAF monoclonal antibody", "stage_raw": "Phase I", "results_date": "May 2019", "nct_id": "NCT04324112", "ct_url": "https://clinicaltrials.gov/study/NCT04324112", "ct_title": "Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL", "ct_status": "RECRUITING"}, {"name": "Crizotinib", "tumor": "Other", "company_us": "US: Therapeutics, EU: Chemokines", "company_eu": "EU: Chemokines", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Leukemia: AML", "moa_raw": "NK Cells", "stage_raw": "Mar 2022", "results_date": "NK Cells", "nct_id": "NCT02551718", "ct_url": "https://clinicaltrials.gov/study/NCT02551718", "ct_title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "ct_status": "COMPLETED"}, {"name": "Cabazitaxel", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Exelixis", "company_eu": "EU: Exelixis", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "MET, RET, VEGFR, KIT, AXL inhibitor", "stage_raw": "Jun 2021", "results_date": "MET, RET, VEGFR, KIT, AXL inhibitor", "nct_id": "NCT01913652", "ct_url": "https://clinicaltrials.gov/study/NCT01913652", "ct_title": "Ph II Cabazitaxel DD Liposarcoma", "ct_status": "COMPLETED"}, {"name": "Darinaparsin", "tumor": "Solid tumors", "company_us": "US: Arisaema, EU: Arisaema", "company_eu": "EU: Arisaema", "line": "Second line", "stage": "Other", "year": "", "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Nov 2022", "results_date": "Anti-PD-1 monoclonal antibody", "nct_id": "NCT00423644", "ct_url": "https://clinicaltrials.gov/study/NCT00423644", "ct_title": "A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b", "ct_status": "UNKNOWN"}, {"name": "TAX-CTL4", "tumor": "Solid tumors", "company_us": "US: Children's, EU: Children's, National", "company_eu": "EU: Children's National", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "multi-TAX specific CTLs", "stage_raw": "Sep 2020", "results_date": "multi-TAX specific CTLs", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Abemaciclib", "tumor": "Other", "company_us": "US: Eli Lilly, EU: Eli Lilly", "company_eu": "EU: Eli Lilly", "line": "First line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "CNS: Glioma", "moa_raw": "CDK4/6 inhibitor", "stage_raw": "Oct 2019", "results_date": "CDK4/6 inhibitor", "nct_id": "NCT06413706", "ct_url": "https://clinicaltrials.gov/study/NCT06413706", "ct_title": "A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy", "ct_status": "RECRUITING"}, {"name": "Cabiralizumab", "tumor": "Solid tumors", "company_us": "US: Roche, EU: Roche", "company_eu": "EU: Roche", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "MEK inhibitor", "stage_raw": "Sep 2022", "results_date": "MEK inhibitor", "nct_id": "NCT04050462", "ct_url": "https://clinicaltrials.gov/study/NCT04050462", "ct_title": "Nivolumab Combined With BMS-986253 in HCC Patients", "ct_status": "TERMINATED"}, {"name": "Trastuzumab", "tumor": "Solid tumors", "company_us": "US: Daiichi, EU: Daiichi", "company_eu": "EU: Daiichi", "line": "Second line", "stage": "Other", "year": "", "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Jun 2017", "results_date": "Anti-PD-1 monoclonal antibody", "nct_id": "NCT02131064", "ct_url": "https://clinicaltrials.gov/study/NCT02131064", "ct_title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "ct_status": "COMPLETED"}, {"name": "Nivolumab", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Bristol-Myers, EU: BMS, National University", "company_eu": "EU: National University", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Alkyating agent", "stage_raw": "Jul 2016", "results_date": "Alkyating agent", "nct_id": "NCT03316274", "ct_url": "https://clinicaltrials.gov/study/NCT03316274", "ct_title": "Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma", "ct_status": "COMPLETED"}, {"name": "NK cells", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: NCI, EU: NCI", "company_eu": "EU: NCI", "line": "Second line", "stage": "Other", "year": "", "moa": "Natural Killer Cells", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Natural Killer Cells", "stage_raw": "Aug 2020", "results_date": "Natural Killer Cells", "nct_id": "NCT01621477", "ct_url": "https://clinicaltrials.gov/study/NCT01621477", "ct_title": "T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant", "ct_status": "TERMINATED"}, {"name": "Sorafenib", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Bayer, EU: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Multikinase inhibitor", "stage_raw": "Oct 2018", "results_date": "Multikinase inhibitor", "nct_id": "NCT00837148", "ct_url": "https://clinicaltrials.gov/study/NCT00837148", "ct_title": "Sorafenib and Dacarbazine in Soft Tissue Sarcoma", "ct_status": "COMPLETED"}, {"name": "Ripasudil", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Bayer, EU: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "KIT inhibitor", "stage_raw": "Jun 2017", "results_date": "KIT inhibitor", "nct_id": "NCT03813056", "ct_url": "https://clinicaltrials.gov/study/NCT03813056", "ct_title": "Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy", "ct_status": "RECRUITING"}, {"name": "Veliparib", "tumor": "Solid tumors", "company_us": "US: Veeva, EU: Idexx", "company_eu": "EU: Idexx", "line": "Second line", "stage": "Other", "year": "", "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Apr 2017", "results_date": "Topoisomerase I inhibitor", "nct_id": "NCT03123211", "ct_url": "https://clinicaltrials.gov/study/NCT03123211", "ct_title": "Expanded Access to Veliparib", "ct_status": "NO_LONGER_AVAILABLE"}, {"name": "Palbociclib", "tumor": "Solid tumors", "company_us": "US: Celgene, EU: Generic", "company_eu": "EU: Generic", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase inhibitor", "stage_raw": "Mar 2016", "results_date": "Topoisomerase inhibitor", "nct_id": "NCT02626507", "ct_url": "https://clinicaltrials.gov/study/NCT02626507", "ct_title": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer", "ct_status": "UNKNOWN"}, {"name": "Adavosertib", "tumor": "Solid tumors", "company_us": "US: Estrogen, EU: Estrogen Therapeutics", "company_eu": "EU: Estrogen Therapeutics", "line": "First line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "EGFR inhibitor", "stage_raw": "Sep 2017", "results_date": "EGFR inhibitor", "nct_id": "NCT01047007", "ct_url": "https://clinicaltrials.gov/study/NCT01047007", "ct_title": "A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005", "ct_status": "TERMINATED"}, {"name": "Regorafenib", "tumor": "Solid tumors", "company_us": "US: Bayer, EU: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Other", "year": "", "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Jun 2017", "results_date": "Anti-PD-1 monoclonal antibody", "nct_id": "NCT04008511", "ct_url": "https://clinicaltrials.gov/study/NCT04008511", "ct_title": "Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer", "ct_status": "UNKNOWN"}, {"name": "Trabectedin", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Loxo, EU: Oncogenesis", "company_eu": "EU: Oncogenesis", "line": "First line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Hypoxia-activated prodrug", "stage_raw": "Jul 2015", "results_date": "Hypoxia-activated prodrug", "nct_id": "NCT02618122", "ct_url": "https://clinicaltrials.gov/study/NCT02618122", "ct_title": "A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece", "ct_status": "COMPLETED"}, {"name": "JX-594", "tumor": "Other", "company_us": "US: Fibrocoll, EU: Fibrocoll Neurofibromas", "company_eu": "EU: Fibrocoll Neurofibromas", "line": "Second line", "stage": "Other", "year": "", "moa": "Cancer vaccine", "tumor_raw": "CNS: Neurofibromas", "moa_raw": "Cancer vaccine", "stage_raw": "May 2014", "results_date": "Cancer vaccine", "nct_id": "NCT01169584", "ct_url": "https://clinicaltrials.gov/study/NCT01169584", "ct_title": "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients", "ct_status": "COMPLETED"}, {"name": "Oncolytics-1", "tumor": "Solid tumors", "company_us": "US: Transgene, EU: Transgene", "company_eu": "EU: Transgene", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Oncolytic virus", "stage_raw": "Jan 2019", "results_date": "Oncolytic virus", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Alburto", "tumor": "Solid tumors", "company_us": "US: Biodesigns, EU: Biodesigns", "company_eu": "EU: Biodesigns", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Astrza 4 kinase inhibitor", "stage_raw": "Feb 2019", "results_date": "Astrza 4 kinase inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Winteragia", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Generic, EU: Roche", "company_eu": "EU: Roche", "line": "Fourth line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "SMO inhibitor", "stage_raw": "Jun 2012", "results_date": "SMO inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Aritmab", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "EU: Pfizer", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "VEGFR inhibitor", "stage_raw": "Jun 2019", "results_date": "VEGFR inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Isoratane", "tumor": "CNS: Medulloblastoma", "company_us": "US: Salk Pharmaceutical, EU: Salk", "company_eu": "EU: Salk", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "CNS: Medulloblastoma", "moa_raw": "SMO inhibitor", "stage_raw": "Jan 2012", "results_date": "SMO inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CEP897", "tumor": "CNS: Medulloblastoma", "company_us": "US: Biomarkers, EU: Biomarkers", "company_eu": "EU: Biomarkers", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "CNS: Medulloblastoma", "moa_raw": "IRL-7", "stage_raw": "Jan 2012", "results_date": "IRL-7", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TIC-Medulloblastoma", "tumor": "CNS: Medulloblastoma", "company_us": "US: Salk, EU: Salk", "company_eu": "EU: Salk", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "CNS: Medulloblastoma", "moa_raw": "NCI-NCM inhibitor", "stage_raw": "Apr 2025", "results_date": "NCI-NCM inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Alfitinib", "tumor": "Solid tumors", "company_us": "US: Adhesion Therapeutics, EU: Adhesion", "company_eu": "EU: Adhesion", "line": "Preclinical", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "FGF-H4 inhibitor", "stage_raw": "Dec 2025", "results_date": "FGF-H4 inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Sorafenib", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Advaio, EU: Advaio Pharma", "company_eu": "EU: Advaio Pharma", "line": "Preclinical", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "FGFH4 inhibitor", "stage_raw": "Dec 2025", "results_date": "FGFH4 inhibitor", "nct_id": "NCT00837148", "ct_url": "https://clinicaltrials.gov/study/NCT00837148", "ct_title": "Sorafenib and Dacarbazine in Soft Tissue Sarcoma", "ct_status": "COMPLETED"}, {"name": "Trabectidin", "tumor": "Solid tumors", "company_us": "US: Chia Ta, EU: Chia Ta", "company_eu": "EU: Chia Ta", "line": "First line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "RTVK/EGFR inhibitor", "stage_raw": "Jun 2021", "results_date": "RTVK/EGFR inhibitor", "nct_id": "NCT00060944", "ct_url": "https://clinicaltrials.gov/study/NCT00060944", "ct_title": "A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer", "ct_status": "COMPLETED"}, {"name": "Tandutinib", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Incytes, EU: Incytes Medicines", "company_eu": "EU: Incytes Medicines", "line": "Second line", "stage": "Other", "year": "", "moa": "HDAC inhibitor", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "HDAC inhibitor", "stage_raw": "Jun 2024", "results_date": "HDAC inhibitor", "nct_id": "NCT00064584", "ct_url": "https://clinicaltrials.gov/study/NCT00064584", "ct_title": "Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)", "ct_status": "COMPLETED"}, {"name": "Periplocin", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: All About Combination, EU: All About", "company_eu": "EU: All About", "line": "First line", "stage": "Other", "year": "", "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Sep 2022", "results_date": "Anti-PD-1 monoclonal antibody", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Andsib", "tumor": "Other", "company_us": "US: Chia Ta, EU: Chia Ta", "company_eu": "EU: Chia Ta", "line": "First line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Solid tissue sarcoma (STS)", "moa_raw": "ITKV/EGFR inhibitor", "stage_raw": "Dec 2022", "results_date": "ITKV/EGFR inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Niraparib", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Juncus, EU: Juncus Pharmaceutical", "company_eu": "EU: Juncus Pharmaceutical", "line": "Second line", "stage": "Other", "year": "", "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Alkyating agent", "stage_raw": "Nov 2022", "results_date": "Alkyating agent", "nct_id": "NCT05174455", "ct_url": "https://clinicaltrials.gov/study/NCT05174455", "ct_title": "Niraparib for the Treatment of Leiomyosarcoma", "ct_status": "WITHDRAWN"}, {"name": "FP1-50", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: NCI, EU: NCI", "company_eu": "EU: NCI", "line": "Second line", "stage": "Other", "year": "", "moa": "Microtubule inhibitor", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Microtubule inhibitor", "stage_raw": "Apr 2025", "results_date": "Microtubule inhibitor", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pogliglitazone", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Intas Pharmaceuticals, EU: Intas", "company_eu": "EU: Intas", "line": "Second line", "stage": "Phase III", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "PEG G-CSF", "stage_raw": "Phase III", "results_date": "Sep 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Regorafenib", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Elevar Therapeutics, EU: Elevar", "company_eu": "EU: Elevar", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2027", "nct_id": "NCT02389244", "ct_url": "https://clinicaltrials.gov/study/NCT02389244", "ct_title": "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "MBIS-NIH-Brigatinomab", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Manhattan Biosolutions, EU: Manhattan", "company_eu": "EU: Manhattan", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Anti-XX ADC monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Jan 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Immunicacumab", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Summit Therapeutics, EU: Summit", "company_eu": "EU: Summit", "line": "First line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Anti-PD-1/TVEGF bispecific monoclonal antibody", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GLF-CAR-NK EGFR", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Wellganz, EU: Johannesg Wellganz", "company_eu": "EU: Johannesg Wellganz", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "EGFR CAR-NK Cells", "stage_raw": "Preclinical", "results_date": "Jul 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Darinaparsin", "tumor": "Solid tumors", "company_us": "US: Pharmaceticals, EU: Jazz Pharmaceticals", "company_eu": "EU: Jazz Pharmaceticals", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "DRD2 antagonist", "stage_raw": "Phase I", "results_date": "Sep 2023", "nct_id": "NCT00423644", "ct_url": "https://clinicaltrials.gov/study/NCT00423644", "ct_title": "A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b", "ct_status": "UNKNOWN"}, {"name": "CD2-CAR-T", "tumor": "Solid tumors", "company_us": "US: Adelado, EU: Royal Adelado", "company_eu": "EU: Royal Adelado", "line": "First line", "stage": "Phase I", "year": 2021.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART CD2", "stage_raw": "Phase I", "results_date": "Jun 2021", "nct_id": "NCT06046040", "ct_url": "https://clinicaltrials.gov/study/NCT06046040", "ct_title": "TmPSMA-02 in mCRPC", "ct_status": "RECRUITING"}, {"name": "Cyclophosphamide-Combination", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Nevaker, EU: Nevaker", "company_eu": "EU: Nevaker", "line": "First line", "stage": "Phase IV", "year": 2025.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Alkyating agent", "stage_raw": "Phase IV", "results_date": "Oct 2025", "nct_id": "NCT02180867", "ct_url": "https://clinicaltrials.gov/study/NCT02180867", "ct_title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "LX-101", "tumor": "Solid tumors", "company_us": "US: Loxo Therapeutics, EU: Loxo", "company_eu": "EU: Loxo", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "IGF-methotrexate conjugate", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "NCT06196827", "ct_url": "https://clinicaltrials.gov/study/NCT06196827", "ct_title": "Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "DAFMO", "tumor": "Ewing Sarcoma", "company_us": "US: Milton S, EU: Milton S", "company_eu": "EU: Milton S", "line": "Second line", "stage": "Phase II", "year": 2031.0, "moa": "ODC inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "ODC inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2031", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Xaurtamab", "tumor": "Ewing Sarcoma", "company_us": "US: Amgen, EU: Amgen", "company_eu": "EU: Amgen", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-STEAP1/CD3 bispecific monoclonal antibody", "stage_raw": "Phase I", "results_date": "Jul 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "B7-H3-CAR-T Combination", "tumor": "Ewing Sarcoma", "company_us": "US: St. Jude, EU: St. Jude", "company_eu": "EU: St. Jude", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "CART B7-H3", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Nov 2030", "nct_id": "NCT07222735", "ct_url": "https://clinicaltrials.gov/study/NCT07222735", "ct_title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "ST-0156 *", "tumor": "Ewing Sarcoma", "company_us": "US: Space Therapeutics, EU: Space", "company_eu": "EU: Space", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RBM39 degrader", "stage_raw": "Phase I", "results_date": "Dec 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Zarzuritinib", "tumor": "Ewing Sarcoma", "company_us": "US: Exelixis, EU: Exelixis", "company_eu": "EU: Exelixis", "line": "Second line", "stage": "Phase II", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MET, AXL, MER, VEGFR inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Cabozantinib", "tumor": "Ewing Sarcoma", "company_us": "US: Exelixis, EU: Ipsen", "company_eu": "EU: Ipsen", "line": "First line", "stage": "Phase I", "year": 2030.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MET, RET, VEGFR, KIT, AXL inhibitor", "stage_raw": "Phase I", "results_date": "Oct 2030", "nct_id": "NCT05182164", "ct_url": "https://clinicaltrials.gov/study/NCT05182164", "ct_title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas", "ct_status": "RECRUITING"}, {"name": "Andesib", "tumor": "Ewing Sarcoma", "company_us": "US: Chia Ta, EU: Chia Ta", "company_eu": "EU: Chia Ta", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RTVEGFR inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tolicanib", "tumor": "Ewing Sarcoma", "company_us": "US: Ipsen, EU: Ipsen", "company_eu": "EU: Ipsen", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase I", "results_date": "May 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Oromicin", "tumor": "Solid tumors", "company_us": "US: Edison Oncology, EU: Edison Oncology", "company_eu": "EU: Edison Oncology", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "EF386647", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Scientific Services, EU: Scientific Services", "company_eu": "EU: Scientific Services", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "CDO inhibitor", "stage_raw": "Preclinical", "results_date": "Oct 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Hoxox", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Roche Biotech, EU: Roche Biotech", "company_eu": "EU: Roche Biotech", "line": "Preclinical", "stage": "Preclinical", "year": 2029.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "XX degrader", "stage_raw": "Preclinical", "results_date": "Jan 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pegfilgrastim", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Intas Pharmaceuticals, EU: Intas", "company_eu": "EU: Intas", "line": "Second line", "stage": "Phase III", "year": 2024.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "PEG G-CSF", "stage_raw": "Phase III", "results_date": "Sep 2024", "nct_id": "NCT06709495", "ct_url": "https://clinicaltrials.gov/study/NCT06709495", "ct_title": "Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "MBIS-NIH-Brigatinomab", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: Manhattan BioSolutions, EU: Manhattan", "company_eu": "EU: Manhattan", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Anti-XX ADC monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Jan 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CT743 *", "tumor": "Ewing Sarcoma", "company_us": "US: Carrick Therapeutics, EU: Carrick", "company_eu": "EU: Carrick", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CDK12/13 inhibitor / Cyclin K degrader", "stage_raw": "Phase II", "results_date": "Apr 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lifiucci", "tumor": "Ewing Sarcoma", "company_us": "US: Irvance Biotherapeutics, EU: Irvance", "company_eu": "EU: Irvance", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Tumor infiltrating lymphocytes", "stage_raw": "Phase I", "results_date": "Jul 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "KCC106", "tumor": "Ewing Sarcoma", "company_us": "US: Beijing Konunas, EU: Beijing Konunas", "company_eu": "EU: Beijing Konunas", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "FLT3AXLVEGFR2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Serithna", "tumor": "Ewing Sarcoma", "company_us": "US: Senthwa Biosciences, EU: Senthwa", "company_eu": "EU: Senthwa", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CK2 inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "AMX-1501 Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Aminex Therapeutics, EU: Aminex", "company_eu": "EU: Aminex", "line": "Second line", "stage": "Phase II", "year": 2033.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Polyamine transport inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2033", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Zeeuratamab Vedotin", "tumor": "Ewing Sarcoma", "company_us": "US: Merck, EU: MSD", "company_eu": "EU: MSD", "line": "Second line", "stage": "Phase II", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-ROR1 ADC monoclonal antibody", "stage_raw": "Phase II", "results_date": "Mar 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "HEPP9", "tumor": "Ewing Sarcoma", "company_us": "US: CSPC Pharmaceutical, EU: CSPC", "company_eu": "EU: CSPC", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase I", "results_date": "May 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Natalizumab Combination", "tumor": "Ewing Sarcoma", "company_us": "US: CSPC Pharmaceutical, EU: CSPC", "company_eu": "EU: CSPC", "line": "Neoadjuvant Only", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-RANKI monoclonal antibody", "stage_raw": "Phase II", "results_date": "Nov 2026", "nct_id": "NCT01416155", "ct_url": "https://clinicaltrials.gov/study/NCT01416155", "ct_title": "Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis", "ct_status": "COMPLETED"}, {"name": "VG151", "tumor": "Ewing Sarcoma", "company_us": "US: Virgin Biotech, EU: Virgin Biotech", "company_eu": "EU: Virgin Biotech", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Oncolytic virus", "stage_raw": "Phase II", "results_date": "Jul 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "WAC", "tumor": "Ewing Sarcoma", "company_us": "US: University Hospital, EU: University Hospital", "company_eu": "EU: University Hospital", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Jun 2027", "nct_id": "NCT06807723", "ct_url": "https://clinicaltrials.gov/study/NCT06807723", "ct_title": "Further Delineation of the De Santo Shinawi Syndrome Phenotype Using a Series of Individuals Carrying a Pathogenic Variant of the WAC Gene", "ct_status": "RECRUITING"}, {"name": "TIL s Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Shanghai Juncao, EU: Shanghai Juncao", "company_eu": "EU: Shanghai Juncao", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Tumor infiltrating lymphocytes", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT00937625", "ct_url": "https://clinicaltrials.gov/study/NCT00937625", "ct_title": "T-cell Based Immunotherapy for of Melanoma", "ct_status": "COMPLETED"}, {"name": "Erbitium", "tumor": "Ewing Sarcoma", "company_us": "US: Eisai, EU: Eisai", "company_eu": "EU: Eisai", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Microtubule inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Darinaparsin", "tumor": "Ewing Sarcoma", "company_us": "US: Beijing Konunas, EU: Beijing Konunas", "company_eu": "EU: Beijing Konunas", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "FLT3AXLVEGFR2 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "NCT00423644", "ct_url": "https://clinicaltrials.gov/study/NCT00423644", "ct_title": "A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b", "ct_status": "UNKNOWN"}, {"name": "Semirameth", "tumor": "Ewing Sarcoma", "company_us": "US: Senthwa Biosciences, EU: Senthwa", "company_eu": "EU: Senthwa", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CK2 inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eribulin", "tumor": "Ewing Sarcoma", "company_us": "US: Eisai", "company_eu": "EU: Eisai", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Microtubule inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT03441360", "ct_url": "https://clinicaltrials.gov/study/NCT03441360", "ct_title": "Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)", "ct_status": "COMPLETED"}, {"name": "153JEM-DOTMP", "tumor": "Ewing Sarcoma", "company_us": "US: Telix Pharmaceuticals", "company_eu": "EU: Telix Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "DOTMP radioconjugate", "stage_raw": "Phase I", "results_date": "Apr 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Naftamab", "tumor": "Ewing Sarcoma", "company_us": "US: SERB Pharmaceuticals", "company_eu": "EU: SERB Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "May 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Fluzoparib", "tumor": "Ewing Sarcoma", "company_us": "US: Luzsana Biotechnology", "company_eu": "EU: Luzsana Biotechnology", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2024", "nct_id": "NCT06827717", "ct_url": "https://clinicaltrials.gov/study/NCT06827717", "ct_title": "Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma", "ct_status": "RECRUITING"}, {"name": "Lurbinectedin", "tumor": "Ewing Sarcoma", "company_us": "US: Jazz Pharmaceuticals", "company_eu": "EU: PharmaAr", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RNA polymerase II inhibitor", "stage_raw": "Phase II", "results_date": "Jul 2026", "nct_id": "NCT05918640", "ct_url": "https://clinicaltrials.gov/study/NCT05918640", "ct_title": "Lurbinectedin in FET-Fused Tumors", "ct_status": "RECRUITING"}, {"name": "PI454", "tumor": "Ewing Sarcoma", "company_us": "US: PharmaAr", "company_eu": "EU: PharmaAr", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Transcription inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Repotrectinib", "tumor": "Ewing Sarcoma", "company_us": "US: Bayer", "company_eu": "EU: Bayer", "line": "First line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "KIT inhibitor", "stage_raw": "Phase I", "results_date": "May 2025", "nct_id": "NCT06352528", "ct_url": "https://clinicaltrials.gov/study/NCT06352528", "ct_title": "A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment", "ct_status": "COMPLETED"}, {"name": "Amlintinib", "tumor": "Ewing Sarcoma", "company_us": "US: Chia Tai", "company_eu": "EU: Chia Tai", "line": "Second line", "stage": "Phase IV", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RTK/VEGFR inhibitor", "stage_raw": "Phase IV", "results_date": "Dec 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TGF\u03b2 Expanded NK Cells Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Nationwide Children's", "company_eu": "EU: Nationwide Children's", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Allogeneic TGF-\u03b2-impaired expanded NK cells", "stage_raw": "Phase II", "results_date": "Nov 2025", "nct_id": "NCT05634369", "ct_url": "https://clinicaltrials.gov/study/NCT05634369", "ct_title": "A Multi-Institution Study of TGF\u03b2 Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue", "ct_status": "RECRUITING"}, {"name": "GAIA-102 (iv)", "tumor": "Ewing Sarcoma", "company_us": "US: GAIA BioMedicine", "company_eu": "EU: GAIA BioMedicine", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PBMC-derived NK-like cells", "stage_raw": "Phase I", "results_date": "Aug 2027", "nct_id": "NCT05207371", "ct_url": "https://clinicaltrials.gov/study/NCT05207371", "ct_title": "Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC", "ct_status": "UNKNOWN"}, {"name": "225Ac-3BP-227", "tumor": "Ewing Sarcoma", "company_us": "US: 3B Pharmaceuticals", "company_eu": "EU: 3B Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "NTSR1 radioconjugate", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Abemaciclib", "tumor": "Ewing Sarcoma", "company_us": "US: Eli Lilly", "company_eu": "EU: Eli Lilly", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CDK4/6 inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2025", "nct_id": "NCT05440786", "ct_url": "https://clinicaltrials.gov/study/NCT05440786", "ct_title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Nivolumab", "tumor": "Ewing Sarcoma", "company_us": "US: BMS", "company_eu": "EU: BMS", "line": "(Neo)adjuvant", "stage": "Phase II", "year": 2025.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2025", "nct_id": "NCT02304458", "ct_url": "https://clinicaltrials.gov/study/NCT02304458", "ct_title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas", "ct_status": "COMPLETED"}, {"name": "LY2880070 Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Espiras Pharma", "company_eu": "EU: Espiras Pharma", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CHK-1 inhibitor", "stage_raw": "Phase II", "results_date": "Aug 2025", "nct_id": "NCT05275426", "ct_url": "https://clinicaltrials.gov/study/NCT05275426", "ct_title": "A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor", "ct_status": "COMPLETED"}, {"name": "Sciclederstat", "tumor": "Ewing Sarcoma", "company_us": "US: Decoy Therapeutics", "company_eu": "EU: Decoy Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "LSD1 inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TGB2658", "tumor": "Ewing Sarcoma", "company_us": "US: Chia Tai", "company_eu": "EU: Chia Tai", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-L1/TrafB functional fusion protein", "stage_raw": "Phase II", "results_date": "Sep 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Selumetinib", "tumor": "Ewing Sarcoma", "company_us": "US: AstraZeneca", "company_eu": "EU: AstraZeneca", "line": "Second line", "stage": "Phase II", "year": 2031.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MEK inhibitor", "stage_raw": "Phase II", "results_date": "May 2031", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "TAA-1", "tumor": "Ewing Sarcoma", "company_us": "US: Childrens Research", "company_eu": "EU: Childrens Research", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MultiTAA specific CTLs", "stage_raw": "Phase I", "results_date": "Oct 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pembrolizumab", "tumor": "Ewing Sarcoma", "company_us": "US: Merck", "company_eu": "EU: Merck", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2026", "nct_id": "NCT05182164", "ct_url": "https://clinicaltrials.gov/study/NCT05182164", "ct_title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas", "ct_status": "RECRUITING"}, {"name": "Cabozantinib", "tumor": "Ewing Sarcoma", "company_us": "US: Exelixis", "company_eu": "EU: Ipsen", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MET, RET, VEGFR, KIT, AXL inhibitor", "stage_raw": "Phase II", "results_date": "Jul 2026", "nct_id": "NCT05182164", "ct_url": "https://clinicaltrials.gov/study/NCT05182164", "ct_title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas", "ct_status": "RECRUITING"}, {"name": "Trabectedin", "tumor": "Ewing Sarcoma", "company_us": "US: Janssen", "company_eu": "EU: PharmaAr", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Alkylating agent", "stage_raw": "Phase II", "results_date": "Oct 2023", "nct_id": "NCT04067115", "ct_url": "https://clinicaltrials.gov/study/NCT04067115", "ct_title": "SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients", "ct_status": "COMPLETED"}, {"name": "Stiusomab", "tumor": "Ewing Sarcoma", "company_us": "US: Actuate Therapeutics", "company_eu": "EU: Actuate Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "GSK-3b inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2021", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Sputuleusp", "tumor": "Ewing Sarcoma", "company_us": "US: Hutchmed", "company_eu": "EU: Hutchmed", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "VEGFR, FGFR inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CART HER2 Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART HER2", "stage_raw": "Phase I", "results_date": "Jun 2028", "nct_id": "NCT04433221", "ct_url": "https://clinicaltrials.gov/study/NCT04433221", "ct_title": "Combination Immunotherapy Targeting Sarcomas", "ct_status": "UNKNOWN"}, {"name": "Pronicad NM-RS Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Ipsen", "company_eu": "EU: Servier", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "May 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "B7-H3 CART Combination", "tumor": "Ewing Sarcoma", "company_us": "US: St. Jude", "company_eu": "EU: St. Jude", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "CART B7-H3", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Mar 2026", "nct_id": "NCT04432649", "ct_url": "https://clinicaltrials.gov/study/NCT04432649", "ct_title": "Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276", "ct_status": "UNKNOWN"}, {"name": "PEP-566 Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Tarveda Therapeutics", "company_eu": "EU: Tarveda Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "HSP90 targeting ligand", "stage_raw": "Phase II", "results_date": "Feb 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tejanlimab", "tumor": "Ewing Sarcoma", "company_us": "US: Iteron Therapeutics", "company_eu": "EU: Iteron Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "TBL1 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Devimistat", "tumor": "Ewing Sarcoma", "company_us": "US: Cornerstone Pharmaceuticals", "company_eu": "EU: Cornerstone Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Tricarboxylic acid (TCA) cycle inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2023", "nct_id": "NCT02484391", "ct_url": "https://clinicaltrials.gov/study/NCT02484391", "ct_title": "CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma", "ct_status": "COMPLETED"}, {"name": "Toripaltimab", "tumor": "Ewing Sarcoma", "company_us": "US: Coherus Oncology", "company_eu": "EU: Coherus Oncology", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jan 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nerapamib", "tumor": "Ewing Sarcoma", "company_us": "US: GSK", "company_eu": "EU: GSK", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Etirinotecan", "tumor": "Ewing Sarcoma", "company_us": "US: Novartis", "company_eu": "EU: Novartis", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "TPO-R agonist", "stage_raw": "Phase I", "results_date": "May 2025", "nct_id": "NCT01773109", "ct_url": "https://clinicaltrials.gov/study/NCT01773109", "ct_title": "Etirinotecan Pegol (NKTR-102) in NSCLC", "ct_status": "COMPLETED"}, {"name": "SCRI-CARB7-HS", "tumor": "Ewing Sarcoma", "company_us": "US: Seattle Children's", "company_eu": "EU: Seattle Children's", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "CART B7-H3", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "4SCAR-GD2", "tumor": "Ewing Sarcoma", "company_us": "US: Shenzhen Genentech", "company_eu": "EU: Shenzhen Genentech", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "CART GD2", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART GD2", "stage_raw": "Phase II", "results_date": "May 2023", "nct_id": "NCT04430595", "ct_url": "https://clinicaltrials.gov/study/NCT04430595", "ct_title": "Multi-4SCAR-T Therapy Targeting Breast Cancer", "ct_status": "UNKNOWN"}, {"name": "Oral inilocarp", "tumor": "Ewing Sarcoma", "company_us": "US: Edison Oncology", "company_eu": "EU: Edison Oncology", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase I", "results_date": "Apr 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Selepamtab", "tumor": "Ewing Sarcoma", "company_us": "US: Eli Lilly", "company_eu": "EU: Eli Lilly", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RET inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Voroxolar", "tumor": "Ewing Sarcoma", "company_us": "US: Merck", "company_eu": "EU: Merck", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "HDAC inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tipifarnib", "tumor": "Ewing Sarcoma", "company_us": "US: Kura Oncology", "company_eu": "EU: Kura Oncology", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Farnesyl transferase inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2024", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Etiplaigis", "tumor": "Ewing Sarcoma", "company_us": "US: Actuate Therapeutics", "company_eu": "EU: Actuate Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "GSK-3b inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ENS-001", "tumor": "Ewing Sarcoma", "company_us": "US: ENB Therapeutics", "company_eu": "EU: ENB Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Endothelin B Receptor antagonist", "stage_raw": "Phase II", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Novusidib", "tumor": "Ewing Sarcoma", "company_us": "US: Servier", "company_eu": "EU: Servier", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "IDH1 inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BIO-11006", "tumor": "Ewing Sarcoma", "company_us": "US: BioMerck Pharmaceuticals", "company_eu": "EU: BioMerck Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MARCKS inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2024", "nct_id": "NCT04183062", "ct_url": "https://clinicaltrials.gov/study/NCT04183062", "ct_title": "BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases", "ct_status": "WITHDRAWN"}, {"name": "Palbociclib", "tumor": "Ewing Sarcoma", "company_us": "US: Pfizer", "company_eu": "EU: Pfizer", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CDK4/6 inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2022", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Selincro", "tumor": "Ewing Sarcoma", "company_us": "US: Karyopharm", "company_eu": "EU: Karyopharm", "line": "Second line", "stage": "Phase I", "year": 2020.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CRM1 inhibitor", "stage_raw": "Phase I", "results_date": "Nov 2020", "nct_id": "NCT02679469", "ct_url": "https://clinicaltrials.gov/study/NCT02679469", "ct_title": "A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects", "ct_status": "COMPLETED"}, {"name": "Gemenovalucel-T", "tumor": "Ewing Sarcoma", "company_us": "US: Gradalis", "company_eu": "EU: Gradalis", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Feb 2021", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ocu8pan", "tumor": "Ewing Sarcoma", "company_us": "US: Inbiota Biosciences", "company_eu": "EU: Inbiota Biosciences", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-DR5 multivalent antibody", "stage_raw": "Phase I", "results_date": "Sep 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ulistinib", "tumor": "Ewing Sarcoma", "company_us": "US: Beckley Valley", "company_eu": "EU: Beckley Valley", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "ERK inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "EGFR60CD19 CART Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Baylor College", "company_eu": "EU: Baylor College", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART EGFR60CD19", "stage_raw": "Phase I", "results_date": "May 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TP-1267", "tumor": "Ewing Sarcoma", "company_us": "US: Sumitomo Pharma", "company_eu": "EU: Sumitomo Pharma", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CDK9 inhibitor", "stage_raw": "Phase I", "results_date": "May 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Antiolsib", "tumor": "Ewing Sarcoma", "company_us": "US: Chia Tai", "company_eu": "EU: Chia Tai", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RTK/VEGFR inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Gemenovalucel-T Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Gradalis", "company_eu": "EU: Gradalis", "line": "Second line", "stage": "Phase III", "year": 2022.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase III", "results_date": "Dec 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Rivoceranib", "tumor": "Ewing Sarcoma", "company_us": "US: Elevar Therapeutics", "company_eu": "EU: Elevar Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2016.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2016", "nct_id": "NCT05320692", "ct_url": "https://clinicaltrials.gov/study/NCT05320692", "ct_title": "A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Ipolisulfine 1-131", "tumor": "Ewing Sarcoma", "company_us": "US: Celecular Biosciences", "company_eu": "EU: Celecular Biosciences", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Radiopharmaceutical", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pegarginase Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Polaris Group", "company_eu": "EU: Polaris Group", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Arginine deiminase", "stage_raw": "Phase II", "results_date": "Jun 2021", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mecbdamab vicivia", "tumor": "Ewing Sarcoma", "company_us": "US: BioAta", "company_eu": "EU: BioAta", "line": "Third line", "stage": "Phase II", "year": 2020.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-AXL ADC monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GD2-CART01", "tumor": "Ewing Sarcoma", "company_us": "US: Ospedale Bambino", "company_eu": "EU: Ospedale Bambino", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "CART GD2", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Apr 2023", "nct_id": "NCT03373097", "ct_url": "https://clinicaltrials.gov/study/NCT03373097", "ct_title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "4SCAR-JT", "tumor": "Ewing Sarcoma", "company_us": "US: Shenzhen Genentech", "company_eu": "EU: Genentech", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART sarcoma-specific", "stage_raw": "Phase II", "results_date": "Nov 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lenvatinib Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Eisai", "company_eu": "EU: Eisai", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "VEGFR, FGFR inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2022", "nct_id": "NCT03245151", "ct_url": "https://clinicaltrials.gov/study/NCT03245151", "ct_title": "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors", "ct_status": "COMPLETED"}, {"name": "Oloapamb", "tumor": "Ewing Sarcoma", "company_us": "US: AstraZeneca", "company_eu": "EU: AstraZeneca", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Venturianib", "tumor": "Ewing Sarcoma", "company_us": "US: Genentech", "company_eu": "EU: Roche", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "BRAF inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tazemelcostat", "tumor": "Ewing Sarcoma", "company_us": "US: Ipsen", "company_eu": "EU: Ipsen", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "BRAF inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lirudestinib", "tumor": "Ewing Sarcoma", "company_us": "US: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "EZH2 inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Emcarbetinib", "tumor": "Ewing Sarcoma", "company_us": "US: Xconery", "company_eu": "EU: Xconery", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "NTRK inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Entaflaxin", "tumor": "Ewing Sarcoma", "company_us": "US: Janssen", "company_eu": "EU: Janssen", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PdR FGFR inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NAB-Arolimus Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Kaken Pharmaceuticals", "company_eu": "EU: Kaken Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "mTOR inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Paxolticinib", "tumor": "Ewing Sarcoma", "company_us": "US: Novartis", "company_eu": "EU: Novartis", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "VEGFR inhibitor", "stage_raw": "Phase I", "results_date": "Oct 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Doxorubicine", "tumor": "Ewing Sarcoma", "company_us": "US: Jazz Pharmaceuticals", "company_eu": "EU: Jazz Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "DRD2 antagonist", "stage_raw": "Phase II", "results_date": "Jan 2022", "nct_id": "NCT01112800", "ct_url": "https://clinicaltrials.gov/study/NCT01112800", "ct_title": "Markers of Anthracycline-Related Cardiac Muscle Injury", "ct_status": "WITHDRAWN"}, {"name": "Erottiminab", "tumor": "Ewing Sarcoma", "company_us": "US: MacroGenics", "company_eu": "EU: MacroGenics", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-B7-H3 monoclonal antibody", "stage_raw": "Phase I", "results_date": "May 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CHI4001 Combination", "tumor": "Ewing Sarcoma", "company_us": "US: Childrens Therapeutics", "company_eu": "EU: Childrens Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "NK Cells", "stage_raw": "Phase I", "results_date": "Mar 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "VAA-CTLs", "tumor": "Ewing Sarcoma", "company_us": "US: Childrens National", "company_eu": "EU: Childrens National", "line": "Second line", "stage": "Phase I", "year": 2020.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MultiTAA specific CTLs", "stage_raw": "Phase I", "results_date": "Sep 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "pbi-shRNA EWS/FLI1 Type 1 LPX", "tumor": "Ewing Sarcoma", "company_us": "US: Gradalis", "company_eu": "EU: Gradalis", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "pbi-shRNA", "stage_raw": "Phase I", "results_date": "Aug 2019", "nct_id": "NCT02736565", "ct_url": "https://clinicaltrials.gov/study/NCT02736565", "ct_title": "Pbi-shRNA\u2122 EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma", "ct_status": "COMPLETED"}, {"name": "Lirudestinib", "tumor": "Ewing Sarcoma", "company_us": "US: Astellas", "company_eu": "EU: Astellas", "line": "Second line", "stage": "Phase II", "year": 2016.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "IGF-1R inhibitor", "stage_raw": "Phase II", "results_date": "Jul 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Atezolizumab", "tumor": "Ewing Sarcoma", "company_us": "US: Genentech", "company_eu": "EU: Roche", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-L1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jun 2017", "nct_id": "NCT05746481", "ct_url": "https://clinicaltrials.gov/study/NCT05746481", "ct_title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases", "ct_status": "TERMINATED"}, {"name": "AlbiSCT", "tumor": "Ewing Sarcoma", "company_us": "US: University of", "company_eu": "EU: University of", "line": "Second line", "stage": "Phase I", "year": 2016.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Allogeneic Stem Cell Transplantation", "stage_raw": "Phase I", "results_date": "Dec 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lurbinectedin", "tumor": "Ewing Sarcoma", "company_us": "US: PharmaAr", "company_eu": "EU: PharmaAr", "line": "Second line", "stage": "Approved", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RNA polymerase II inhibitor", "stage_raw": "Approved", "results_date": "Nov 2017", "nct_id": "NCT05918640", "ct_url": "https://clinicaltrials.gov/study/NCT05918640", "ct_title": "Lurbinectedin in FET-Fused Tumors", "ct_status": "RECRUITING"}, {"name": "NK cells", "tumor": "Ewing Sarcoma", "company_us": "US: National University", "company_eu": "EU: National University", "line": "Second line", "stage": "Phase II", "year": 2020.0, "moa": "NK cells", "tumor_raw": "Ewing Sarcoma", "moa_raw": "NK cells", "stage_raw": "Phase II", "results_date": "Aug 2020", "nct_id": "NCT00788125", "ct_url": "https://clinicaltrials.gov/study/NCT00788125", "ct_title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "ct_status": "TERMINATED"}, {"name": "Posaterlinib", "tumor": "Ewing Sarcoma", "company_us": "US: Daiichi Sankyo", "company_eu": "EU: Daiichi Sankyo", "line": "Second line", "stage": "Phase I", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CSF-1R inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ganitumab", "tumor": "Ewing Sarcoma", "company_us": "US: Immunolytico", "company_eu": "EU: Immunolytico", "line": "First line", "stage": "Phase III", "year": 2021.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-IGF-IR monoclonal antibody", "stage_raw": "Phase III", "results_date": "Mar 2021", "nct_id": "NCT00562380", "ct_url": "https://clinicaltrials.gov/study/NCT00562380", "ct_title": "AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma", "ct_status": "COMPLETED"}, {"name": "tvm4-186322A", "tumor": "Ewing Sarcoma", "company_us": "US: Essential Pharma", "company_eu": "EU: Essential Pharma", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Oct 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Debrinzumab", "tumor": "Ewing Sarcoma", "company_us": "US: Novartis", "company_eu": "EU: Novartis", "line": "Second line", "stage": "Approved", "year": 2018.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "BRAF inhibitor", "stage_raw": "Approved", "results_date": "Jun 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NLI-Cells", "tumor": "Ewing Sarcoma", "company_us": "US: NCI", "company_eu": "EU: NCI", "line": "Second line", "stage": "Phase II", "year": 2020.0, "moa": "Natural Killer Cells", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Natural Killer Cells", "stage_raw": "Phase II", "results_date": "Dec 2020", "nct_id": "NCT06443151", "ct_url": "https://clinicaltrials.gov/study/NCT06443151", "ct_title": "Role of Endothelial Function in SCI CVD Risk", "ct_status": "RECRUITING"}, {"name": "Rogartenib", "tumor": "Ewing Sarcoma", "company_us": "US: Bayer", "company_eu": "EU: Bayer", "line": "Second line", "stage": "Phase II", "year": 2018.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "KIT inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Giltinib", "tumor": "Ewing Sarcoma", "company_us": "US: GSK", "company_eu": "EU: GSK", "line": "Fifth line", "stage": "Phase I", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "KIT inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Irinolican Nal-IRI", "tumor": "Ewing Sarcoma", "company_us": "US: Ipsen", "company_eu": "EU: Servier", "line": "Second line", "stage": "Phase I", "year": 2018.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase I", "results_date": "Nov 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imielstat", "tumor": "Ewing Sarcoma", "company_us": "US: Geron", "company_eu": "EU: Geron", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imlotstat", "tumor": "Ewing Sarcoma", "company_us": "Geron", "company_eu": "Geron", "line": "Second line", "stage": "Phase II", "year": 2016.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Telomerase inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Olaparib Combination", "tumor": "Ewing Sarcoma", "company_us": "AstraZeneca", "company_eu": "AstraZeneca", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase I", "results_date": "Nov 2024", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "NK-Cells", "tumor": "Ewing Sarcoma", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase II", "year": 2015.0, "moa": "Natural Killer Cells", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Natural Killer Cells", "stage_raw": "Phase II", "results_date": "Dec 2015", "nct_id": "NCT00788125", "ct_url": "https://clinicaltrials.gov/study/NCT00788125", "ct_title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "ct_status": "TERMINATED"}, {"name": "Olaparib", "tumor": "Ewing Sarcoma", "company_us": "AstraZeneca", "company_eu": "AstraZeneca", "line": "Second line", "stage": "Phase II", "year": 2014.0, "moa": "PARP inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2014", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Pterostilbene", "tumor": "Ewing Sarcoma", "company_us": "Sanofi", "company_eu": "Sanofi", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CXC/64 antagonist", "stage_raw": "Phase II", "results_date": "May 2017", "nct_id": "NCT02819219", "ct_url": "https://clinicaltrials.gov/study/NCT02819219", "ct_title": "Effects of ElevATP on Body Composition and Athletic Performance", "ct_status": "COMPLETED"}, {"name": "DC vaccine", "tumor": "Ewing Sarcoma", "company_us": "Tricision BioTherapeutics", "company_eu": "Tricision BioTherapeutics", "line": "Second line", "stage": "Phase I", "year": 2014.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "May 2014", "nct_id": "NCT01241162", "ct_url": "https://clinicaltrials.gov/study/NCT01241162", "ct_title": "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma", "ct_status": "COMPLETED"}, {"name": "PM00104", "tumor": "Ewing Sarcoma", "company_us": "PharmaMar", "company_eu": "PharmaMar", "line": "Second line", "stage": "Phase II", "year": 2012.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Alkylating agent", "stage_raw": "Phase II", "results_date": "Apr 2012", "nct_id": "NCT01222767", "ct_url": "https://clinicaltrials.gov/study/NCT01222767", "ct_title": "Study of Zalypsis\u00ae (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy", "ct_status": "COMPLETED"}, {"name": "Pexidartinib derivatives", "tumor": "Ewing Sarcoma", "company_us": "Transgene", "company_eu": "Transgene", "line": "Second line", "stage": "Phase I", "year": 2015.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Oncolytic virus", "stage_raw": "Phase I", "results_date": "Jan 2015", "nct_id": "NCT03291288", "ct_url": "https://clinicaltrials.gov/study/NCT03291288", "ct_title": "Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)", "ct_status": "COMPLETED"}, {"name": "Alberito", "tumor": "Ewing Sarcoma", "company_us": "Puma Biotechnology", "company_eu": "Puma Biotechnology", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Aurora A kinase inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Virotoxin Combination", "tumor": "Ewing Sarcoma", "company_us": "Genentech", "company_eu": "Roche", "line": "Fourth line", "stage": "Phase II", "year": 2012.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "SMO inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2012", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Gemcitabine/docetaxel-T", "tumor": "Ewing Sarcoma", "company_us": "Gradalis", "company_eu": "Gradalis", "line": "Second line", "stage": "Phase I", "year": 2018.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "Mar 2018", "nct_id": "NCT03006614", "ct_url": "https://clinicaltrials.gov/study/NCT03006614", "ct_title": "PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer", "ct_status": "UNKNOWN"}, {"name": "Zoledronic acid", "tumor": "Ewing Sarcoma", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase III", "year": 2019.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Bisphosphonate", "stage_raw": "Phase III", "results_date": "Mar 2019", "nct_id": "NCT06625190", "ct_url": "https://clinicaltrials.gov/study/NCT06625190", "ct_title": "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors", "ct_status": "RECRUITING"}, {"name": "Pazopanib", "tumor": "Ewing Sarcoma", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2011.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "VEGFR inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2011", "nct_id": "NCT01542047", "ct_url": "https://clinicaltrials.gov/study/NCT01542047", "ct_title": "A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies", "ct_status": "TERMINATED"}, {"name": "11C-Methionine PET/MRI", "tumor": "Ewing Sarcoma", "company_us": "St. Jude", "company_eu": "St. Jude", "line": "First line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Amino acid radioconjugate", "stage_raw": "Phase II", "results_date": "Jul 2027", "nct_id": "NCT01873469", "ct_url": "https://clinicaltrials.gov/study/NCT01873469", "ct_title": "Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme", "ct_status": "COMPLETED"}, {"name": "hrl4.16K322A", "tumor": "Ewing Sarcoma", "company_us": "Essential Pharma", "company_eu": "Essential Pharma", "line": "Second line", "stage": "Phase I", "year": 2011.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Jun 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NK-Cells Combination", "tumor": "Ewing Sarcoma", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2021.0, "moa": "Natural Killer Cells", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Natural Killer Cells", "stage_raw": "Phase I", "results_date": "Apr 2021", "nct_id": "NCT00788125", "ct_url": "https://clinicaltrials.gov/study/NCT00788125", "ct_title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "ct_status": "TERMINATED"}, {"name": "Gantisumab", "tumor": "Ewing Sarcoma", "company_us": "Immuno-Bio", "company_eu": "Immuno-Bio", "line": "Second line", "stage": "Phase II", "year": 2009.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-IGF1R monoclonal antibody", "stage_raw": "Phase II", "results_date": "Aug 2009", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Dalantinib", "tumor": "Ewing Sarcoma", "company_us": "BMS", "company_eu": "BMS", "line": "Third line", "stage": "Phase II", "year": 2011.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "BCR-ABL inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "WT1 cancer vaccine Combination", "tumor": "Ewing Sarcoma", "company_us": "Osaka University", "company_eu": "Osaka University", "line": "First line", "stage": "Phase II", "year": 2012.0, "moa": "Cancer vaccine", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Aug 2012", "nct_id": "NCT00433745", "ct_url": "https://clinicaltrials.gov/study/NCT00433745", "ct_title": "Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy", "ct_status": "COMPLETED"}, {"name": "CVAX-UCLA", "tumor": "Ewing Sarcoma", "company_us": "CancerVAX", "company_eu": "CancerVAX", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-XOYY Biopspicific antibody", "stage_raw": "Preclinical", "results_date": "Jun 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tucsitinib Combination", "tumor": "Ewing Sarcoma", "company_us": "MD Bioscience", "company_eu": "MD Bioscience", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "HDAC inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eribulin Combination", "tumor": "Ewing Sarcoma", "company_us": "Eisai", "company_eu": "Eisai", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Microtubule inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2026", "nct_id": "NCT03441360", "ct_url": "https://clinicaltrials.gov/study/NCT03441360", "ct_title": "Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)", "ct_status": "COMPLETED"}, {"name": "Lurbinectedin", "tumor": "Ewing Sarcoma", "company_us": "Jazz Pharmaceuticals", "company_eu": "PharmaMar", "line": "First line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "RNA polymerase inhibitor", "stage_raw": "Phase II", "results_date": "May 2022", "nct_id": "NCT05918640", "ct_url": "https://clinicaltrials.gov/study/NCT05918640", "ct_title": "Lurbinectedin in FET-Fused Tumors", "ct_status": "RECRUITING"}, {"name": "CCT137690 Combination", "tumor": "Ewing Sarcoma", "company_us": "University of Cape Town", "company_eu": "University of Cape Town", "line": "Preclinical", "stage": "Preclinical", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Aurora kinase inhibitors", "stage_raw": "Preclinical", "results_date": "Apr 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nivolumab Combination", "tumor": "Ewing Sarcoma", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase IV", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-PD-1-4", "stage_raw": "Phase IV", "results_date": "Jun 2022", "nct_id": "NCT02304458", "ct_url": "https://clinicaltrials.gov/study/NCT02304458", "ct_title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas", "ct_status": "COMPLETED"}, {"name": "Eragotide*", "tumor": "Ewing Sarcoma", "company_us": "Actelion Therapeutics", "company_eu": "Actelion Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "GSK-3b inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Cabozantinib", "tumor": "Ewing Sarcoma", "company_us": "Exelixis", "company_eu": "Ipsen", "line": "Second line", "stage": "Phase IV", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MET, RET, KIT, AXL inhibitor", "stage_raw": "Phase IV", "results_date": "Oct 2025", "nct_id": "NCT05182164", "ct_url": "https://clinicaltrials.gov/study/NCT05182164", "ct_title": "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas", "ct_status": "RECRUITING"}, {"name": "Darcorsbib", "tumor": "Ewing Sarcoma", "company_us": "Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "EGFR inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Disidraspine", "tumor": "Ewing Sarcoma", "company_us": "Jazz Pharmaceuticals", "company_eu": "Jazz Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "DRD2 antagonist", "stage_raw": "Phase I", "results_date": "Sep 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GD2-CAR-T", "tumor": "Ewing Sarcoma", "company_us": "Royal Adelaide", "company_eu": "Royal Adelaide", "line": "First line", "stage": "Phase I", "year": 2021.0, "moa": "CART GD2", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Jun 2021", "nct_id": "NCT03356782", "ct_url": "https://clinicaltrials.gov/study/NCT03356782", "ct_title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas", "ct_status": "UNKNOWN"}, {"name": "AIT-102*", "tumor": "Ewing Sarcoma", "company_us": "Orphat Therapeutics", "company_eu": "Orphat Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Milligramm analogue", "stage_raw": "Preclinical", "results_date": "Jun 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Racotumomab", "tumor": "Ewing Sarcoma", "company_us": "Laboratorios Eusiderma", "company_eu": "Laboratorios Eusiderma", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-p3 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2017", "nct_id": "NCT01598454", "ct_url": "https://clinicaltrials.gov/study/NCT01598454", "ct_title": "Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides", "ct_status": "COMPLETED"}, {"name": "KI-3283*", "tumor": "Ewing Sarcoma", "company_us": "Ratiopharm Therapeutics", "company_eu": "Ratiopharm Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "PARP/HDAC inhibitor", "stage_raw": "Preclinical", "results_date": "Jan 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LX-101*", "tumor": "Ewing Sarcoma", "company_us": "Lexington Therapeutics", "company_eu": "Lexington Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "IGF-methioninate conjugate", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "NCT06196827", "ct_url": "https://clinicaltrials.gov/study/NCT06196827", "ct_title": "Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "XBIO-015 Combination", "tumor": "Ewing Sarcoma", "company_us": "Xeno Biosciences", "company_eu": "Xeno Biosciences", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "DNase platform", "stage_raw": "Phase I", "results_date": "Feb 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "MER-101", "tumor": "Ewing Sarcoma", "company_us": "Merlin Biotech", "company_eu": "Merlin Biotech", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "USP6 mRNA", "stage_raw": "Preclinical", "results_date": "Oct 2027", "nct_id": "NCT00636740", "ct_url": "https://clinicaltrials.gov/study/NCT00636740", "ct_title": "Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients", "ct_status": "COMPLETED"}, {"name": "ABP-STAT3", "tumor": "Ewing Sarcoma", "company_us": "Allay Therapeutics", "company_eu": "Allay Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "STAT3 inhibitor", "stage_raw": "Preclinical", "results_date": "Mar 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LP003", "tumor": "Ewing Sarcoma", "company_us": "Lentho Pharm", "company_eu": "Lentho Pharm", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Anti-GD2/CD3 bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Nov 2028", "nct_id": "NCT06294288", "ct_url": "https://clinicaltrials.gov/study/NCT06294288", "ct_title": "A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants", "ct_status": "COMPLETED"}, {"name": "Regorafenib Combination", "tumor": "Ewing Sarcoma", "company_us": "Bayer", "company_eu": "Bayer", "line": "Second line", "stage": "Phase IV", "year": 2022.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "KIT inhibitor", "stage_raw": "Phase IV", "results_date": "Jun 2022", "nct_id": "NCT02389244", "ct_url": "https://clinicaltrials.gov/study/NCT02389244", "ct_title": "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "MB1 CART:GD2 IL-18", "tumor": "Ewing Sarcoma", "company_us": "Millennia Biomedicine", "company_eu": "Millennia Biomedicine", "line": "Third line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CART GD2 IL-18", "stage_raw": "Phase I", "results_date": "Jul 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tarbiciclib", "tumor": "Ewing Sarcoma", "company_us": "Sellus Life", "company_eu": "Sellus Life", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "CDK9 inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Aflay-XX", "tumor": "Ewing Sarcoma", "company_us": "Allay Therapeutics", "company_eu": "Allay Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2029.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "XX inhibitor", "stage_raw": "Preclinical", "results_date": "Sep 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "PRO CAR-2018", "tumor": "Ewing Sarcoma", "company_us": "PromiCell", "company_eu": "PromiCell", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "STEAP1 CAR-T", "stage_raw": "Preclinical", "results_date": "Feb 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Turiaametab", "tumor": "Ewing Sarcoma", "company_us": "Shanghai Kechow", "company_eu": "Shanghai Kechow", "line": "Second line", "stage": "Phase IV", "year": 2028.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "MEK inhibitor", "stage_raw": "Phase IV", "results_date": "Dec 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Oral irinotecan*", "tumor": "Ewing Sarcoma", "company_us": "Edison Oncology", "company_eu": "Edison Oncology", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2028", "nct_id": "NCT05440786", "ct_url": "https://clinicaltrials.gov/study/NCT05440786", "ct_title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "VG161 Combination", "tumor": "Ewing Sarcoma", "company_us": "Virogen Biotech", "company_eu": "Virogen Biotech", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "Oncolytic virus", "stage_raw": "Phase I", "results_date": "Jan 2024", "nct_id": "NCT06746480", "ct_url": "https://clinicaltrials.gov/study/NCT06746480", "ct_title": "Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma", "ct_status": "RECRUITING"}, {"name": "LP-264", "tumor": "Ewing Sarcoma", "company_us": "Lantern Pharma", "company_eu": "Lantern Pharma", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Ewing Sarcoma", "moa_raw": "DNA alkylator", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Revacumab Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Genentech", "company_eu": "Roche", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-VEGF monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tucinostat", "tumor": "CNS - Neuroblastoma", "company_us": "BeOne Medicines", "company_eu": "HUYA Bioscience", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "HDAC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LLMeG3231 zeta NK cells Combination", "tumor": "Other", "company_us": "Baylor College", "company_eu": "Baylor College", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "Osteosarcoma", "moa_raw": "NKG2D zeta-NK cell-IL-15", "stage_raw": "Phase I", "results_date": "Dec 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ST-6H3048*", "tumor": "Solid tumors", "company_us": "Seed Therapeutics", "company_eu": "Seed Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "RBM39 degrader", "stage_raw": "Phase I", "results_date": "Dec 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nevisumab", "tumor": "CNS - Neuroblastoma", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Apr 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Elapixumab Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Genome", "company_eu": "Genome", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "GlcCer synthase inhibitor", "stage_raw": "Early Phase I", "results_date": "Aug 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Neuroganglioside alpha Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Immuno/Bio", "company_eu": "Immuno/Bio", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "IL-15/IL-15Ra fusion protein", "stage_raw": "Phase II", "results_date": "Feb 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BL101", "tumor": "CNS - Neuroblastoma", "company_us": "St.Urban University", "company_eu": "St.Urban University", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "XX radioconjugate", "stage_raw": "Early Phase I", "results_date": "Jun 2026", "nct_id": "NCT01710644", "ct_url": "https://clinicaltrials.gov/study/NCT01710644", "ct_title": "Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis", "ct_status": "COMPLETED"}, {"name": "Nadirumab Combination", "tumor": "CNS - Neuroblastoma", "company_us": "SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "H-TX-661*", "tumor": "CNS - Neuroblastoma", "company_us": "Hida Therapeutics", "company_eu": "Hida Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2032.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "PHX06 CART", "stage_raw": "Phase I", "results_date": "Jun 2032", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "IRl-15 Combination", "tumor": "CNS - Neuroblastoma", "company_us": "NCI", "company_eu": "NCI", "line": "Sixth line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Recombinant IL-15", "stage_raw": "Phase I", "results_date": "Jun 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CEB-01", "tumor": "Soft tissue sarcoma (STS)", "company_us": "CEROTEX Oncology", "company_eu": "CEROTEX Oncology", "line": "Neoadjuvant Only", "stage": "Phase II", "year": 2029.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "SN-38 nanoparticle", "stage_raw": "Phase II", "results_date": "May 2029", "nct_id": "NCT04619056", "ct_url": "https://clinicaltrials.gov/study/NCT04619056", "ct_title": "First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "TH-CART-027*", "tumor": "Solid tumors", "company_us": "Therapeutixgen", "company_eu": "Therapeutixgen", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART XX", "stage_raw": "Early Phase I", "results_date": "Nov 2028", "nct_id": "NCT06951425", "ct_url": "https://clinicaltrials.gov/study/NCT06951425", "ct_title": "An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors", "ct_status": "NOT_YET_RECRUITING"}, {"name": "NK cells Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Guangzhou Women", "company_eu": "Guangzhou Women", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "NK cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NK cells", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "NCT01576692", "ct_url": "https://clinicaltrials.gov/study/NCT01576692", "ct_title": "Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Tipdecan Combination", "tumor": "Other", "company_us": "Novartis", "company_eu": "Novartis", "line": "First line", "stage": "Phase I", "year": 2030.0, "moa": "Other", "tumor_raw": "CNS - other tumors", "moa_raw": "Topoisomerase inhibitor", "stage_raw": "Early Phase I", "results_date": "Dec 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "YK-CAR GD2/H13", "tumor": "Soft tissue sarcoma (STS)", "company_us": "Molecular Biotechnology", "company_eu": "Molecular Biotechnology", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "CART GD2/H13", "stage_raw": "Phase II", "results_date": "Dec 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Hemotopag Olamine", "tumor": "CNS - Neuroblastoma", "company_us": "Lusitania Biotechnology", "company_eu": "Lusitania Biotechnology", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "TPO-R agonist", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tartafilamab", "tumor": "Other", "company_us": "Amgen", "company_eu": "Amgen", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Lung cancer - SCLC", "moa_raw": "Anti-DLL3/CD3 bispecific monoclonal antibody", "stage_raw": "Phase II", "results_date": "May 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ALK CAR-T", "tumor": "CNS - Neuroblastoma", "company_us": "Boston Children", "company_eu": "Boston Children", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART ALK", "stage_raw": "Phase II", "results_date": "Dec 2027", "nct_id": "NCT06803875", "ct_url": "https://clinicaltrials.gov/study/NCT06803875", "ct_title": "Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma", "ct_status": "RECRUITING"}, {"name": "Liposoma mitochondrio Combination", "tumor": "Solid tumors", "company_us": "CSPC Pharmaceutical", "company_eu": "CSPC Pharmaceutical", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase II inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mipsidasone*", "tumor": "Solid tumors", "company_us": "Nanjing", "company_eu": "Nanjing", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "NKG2D/NKp44 CAR-NK", "stage_raw": "Phase I", "results_date": "Jul 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "PEEL224 Combination", "tumor": "Solid tumors", "company_us": "PEEL Therapeutics", "company_eu": "PEEL Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2030", "nct_id": "NCT06709495", "ct_url": "https://clinicaltrials.gov/study/NCT06709495", "ct_title": "Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas", "ct_status": "RECRUITING"}, {"name": "GD2 CART", "tumor": "CNS - Neuroblastoma", "company_us": "Yale Biotechnology", "company_eu": "Yale Biotechnology", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Early Phase I", "results_date": "Dec 2029", "nct_id": "NCT02761915", "ct_url": "https://clinicaltrials.gov/study/NCT02761915", "ct_title": "A Phase I Trial of Anti-GD2 T-cells (1RG-CART)", "ct_status": "COMPLETED"}, {"name": "Nitrogene", "tumor": "CNS - Neuroblastoma", "company_us": "Kian Immune", "company_eu": "Kian Immune", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Allogeneic NK cells", "stage_raw": "Phase I", "results_date": "Nov 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mediamab", "tumor": "Solid tumors", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NK-Cells", "tumor": "CNS - Neuroblastoma", "company_us": "Sun Yat-sen", "company_eu": "Sun Yat-sen", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Natural Killer Cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Natural Killer Cells", "stage_raw": "Phase I", "results_date": "Nov 2026", "nct_id": "NCT01576692", "ct_url": "https://clinicaltrials.gov/study/NCT01576692", "ct_title": "Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Naxitamab", "tumor": "CNS - Neuroblastoma", "company_us": "SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "First line", "stage": "Phase IV", "year": 2029.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase IV", "results_date": "Dec 2029", "nct_id": "NCT03033303", "ct_url": "https://clinicaltrials.gov/study/NCT03033303", "ct_title": "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Sentanvib", "tumor": "Solid tumors", "company_us": "Setheisa Biosciences", "company_eu": "Setheisa Biosciences", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CK2 inhibitor", "stage_raw": "Phase II", "results_date": "Nov 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tipitanib Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Kura Oncology", "company_eu": "Kura Oncology", "line": "Second line", "stage": "Phase II", "year": 2030.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Farnesyl transferase inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nexitamab Combination", "tumor": "CNS - Neuroblastoma", "company_us": "SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2029.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Irinotecan* Combination", "tumor": "Solid tumors", "company_us": "Pharmaceutical", "company_eu": "CSPC Pharmaceutical", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase II inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2027", "nct_id": "NCT04423965", "ct_url": "https://clinicaltrials.gov/study/NCT04423965", "ct_title": "A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC", "ct_status": "UNKNOWN"}, {"name": "CNM-UI", "tumor": "CNS - Neuroblastoma", "company_us": "Nanjing Children's", "company_eu": "Nanjing Children's", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NKG2D/NKp44 CAR-NK", "stage_raw": "Phase I", "results_date": "Jul 2026", "nct_id": "NCT03257670", "ct_url": "https://clinicaltrials.gov/study/NCT03257670", "ct_title": "Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors", "ct_status": "UNKNOWN"}, {"name": "Naxitamab Combination", "tumor": "CNS - Neuroblastoma", "company_us": "SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2029.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2029", "nct_id": "NCT03033303", "ct_url": "https://clinicaltrials.gov/study/NCT03033303", "ct_title": "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "B7-H3 CART", "tumor": "Solid tumors", "company_us": "Stanford University", "company_eu": "Stanford University", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "CART B7-H3", "tumor_raw": "Solid tumors", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Jul 2029", "nct_id": "NCT04432649", "ct_url": "https://clinicaltrials.gov/study/NCT04432649", "ct_title": "Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276", "ct_status": "UNKNOWN"}, {"name": "Decituximab beta", "tumor": "CNS - Neuroblastoma", "company_us": "Recombati", "company_eu": "Recombati", "line": "First line", "stage": "Phase I", "year": 2030.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Jul 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "AMKT-1501 Combination", "tumor": "CNS - Neuroblastoma", "company_us": "Antmex Therapeutics", "company_eu": "Antmex Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2033.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Polyamine transport inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2033", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Zeimetiamab vedotin", "tumor": "Other", "company_us": "MSD", "company_eu": "MSD", "line": "Second line", "stage": "Phase II", "year": 2029.0, "moa": "Other", "tumor_raw": "Hematologic neoplasms", "moa_raw": "Anti-RORI ADC monoclonal antibody", "stage_raw": "Phase II", "results_date": "Mar 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Rivabotinib", "tumor": "CNS - Neuroblastoma", "company_us": "Elevar Therapeutics", "company_eu": "Elevar Therapeutics", "line": "First line", "stage": "Phase II", "year": 2025.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Gomoltamab", "tumor": "CNS - Neuroblastoma", "company_us": "Eli Lilly", "company_eu": "Eli Lilly", "line": "First line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Nucleotide analogue", "stage_raw": "Phase II", "results_date": "Mar 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "DAC009*", "tumor": "Solid tumors", "company_us": "Hangzhou DAC", "company_eu": "Hangzhou DAC", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-CD56 ADC monoclonal antibody", "stage_raw": "Phase I", "results_date": "Dec 2025", "nct_id": "NCT04219761", "ct_url": "https://clinicaltrials.gov/study/NCT04219761", "ct_title": "National Tunisian Registry of Percutaneous Coronary Intervention", "ct_status": "COMPLETED"}, {"name": "Cabiraunib", "tumor": "Other", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Head & neck cancer", "moa_raw": "IDH2 inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ambicintide", "tumor": "Solid tumors", "company_us": "Versium", "company_eu": "Versium", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "RAF/MEK inhibitor", "stage_raw": "Phase I", "results_date": "Oct 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Avelumab", "tumor": "Other", "company_us": "EU: BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Cancer", "moa_raw": "PD-L1 inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2027", "nct_id": "NCT05687721", "ct_url": "https://clinicaltrials.gov/study/NCT05687721", "ct_title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "ct_status": "WITHDRAWN"}, {"name": "Avelumab", "tumor": "Solid tumors", "company_us": "US: Pfizer, EU: Varian", "company_eu": "Varian", "line": "Second line", "stage": "Phase I", "year": 2029.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "RAF/MEK inhibitor", "stage_raw": "Phase I", "results_date": "Oct 2029", "nct_id": "NCT05687721", "ct_url": "https://clinicaltrials.gov/study/NCT05687721", "ct_title": "Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer", "ct_status": "WITHDRAWN"}, {"name": "Dinutuximab beta", "tumor": "CNS - Neuroblastoma", "company_us": "US: Recordati, EU: Recordati", "company_eu": "Recordati", "line": "Second line", "stage": "Phase III", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase III", "results_date": "Sep 2026", "nct_id": "NCT04221035", "ct_url": "https://clinicaltrials.gov/study/NCT04221035", "ct_title": "High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)", "ct_status": "RECRUITING"}, {"name": "Tislelizumab", "tumor": "Solid tumors", "company_us": "US: Shanghai Junsei, EU: Shanghai Junsei", "company_eu": "Shanghai Junsei", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Tumor infiltrating lymphocytes", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT05314101", "ct_url": "https://clinicaltrials.gov/study/NCT05314101", "ct_title": "TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer", "ct_status": "UNKNOWN"}, {"name": "Nivolumab", "tumor": "CNS - Neuroblastoma", "company_us": "US: SERB Pharmaceuticals, EU: SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "Second line", "stage": "Phase IV", "year": 2027.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase IV", "results_date": "Jun 2027", "nct_id": "NCT07100704", "ct_url": "https://clinicaltrials.gov/study/NCT07100704", "ct_title": "Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab", "ct_status": "RECRUITING"}, {"name": "GD2 CART", "tumor": "CNS - Neuroblastoma", "company_us": "US: University College, EU: University College", "company_eu": "University College", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT02761915", "ct_url": "https://clinicaltrials.gov/study/NCT02761915", "ct_title": "A Phase I Trial of Anti-GD2 T-cells (1RG-CART)", "ct_status": "COMPLETED"}, {"name": "BCI-242", "tumor": "CNS - Neuroblastoma", "company_us": "US: Bilocal, EU: Bilocal", "company_eu": "Bilocal", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Afinitor", "tumor": "Solid tumors", "company_us": "US: Genentech, EU: Roche", "company_eu": "Roche", "line": "Second line", "stage": "Phase III", "year": 2029.0, "moa": "ALK inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "ALK inhibitor", "stage_raw": "Phase III", "results_date": "Oct 2029", "nct_id": "NCT03493165", "ct_url": "https://clinicaltrials.gov/study/NCT03493165", "ct_title": "Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)", "ct_status": "NO_LONGER_AVAILABLE"}, {"name": "Allogene Hematologic", "tumor": "Solid tumors", "company_us": "US: Arcus Biopharm, EU: Arcus Biopharm", "company_eu": "Arcus Biopharm", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "MDM2-p53 inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TRIG/GPC2-01", "tumor": "CNS - Neuroblastoma", "company_us": "US: Gilead, EU: Gilead", "company_eu": "Gilead", "line": "Second line", "stage": "Phase I", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GPC2", "stage_raw": "Phase I", "results_date": "Jan 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Afamitresgene autoleucel", "tumor": "Soft tissue sarcoma (STS)", "company_us": "US: US WorldMeds, EU: US WorldMeds", "company_eu": "US WorldMeds", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "TCR MAGE A4", "stage_raw": "Phase II", "results_date": "Oct 2026", "nct_id": "NCT06617572", "ct_url": "https://clinicaltrials.gov/study/NCT06617572", "ct_title": "Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel", "ct_status": "AVAILABLE"}, {"name": "Lipotecan intralesional", "tumor": "Solid tumors", "company_us": "US: CSPC Pharmaceutical, EU: CSPC Pharmaceutical", "company_eu": "CSPC Pharmaceutical", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase II inhibitor", "stage_raw": "Phase I", "results_date": "May 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GAIA-102-coy", "tumor": "Solid tumors", "company_us": "US: GAIA BioTherapeutics, EU: GAIA BioTherapeutics", "company_eu": "GAIA BioTherapeutics", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "PBMC-derived NK-like cells", "stage_raw": "Phase I", "results_date": "Aug 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TAUS", "tumor": "CNS - Neuroblastoma", "company_us": "US: Persion, EU: Persion Biotherapeutics", "company_eu": "Persion Biotherapeutics", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART CD276", "stage_raw": "Phase I", "results_date": "Dec 2025", "nct_id": "NCT02930720", "ct_url": "https://clinicaltrials.gov/study/NCT02930720", "ct_title": "Pelvic Floor Displacement in Women With SUI and Healthy Women: An Ultrasound Study (Stress Urinary Incontinence)", "ct_status": "UNKNOWN"}, {"name": "Nivolumab", "tumor": "CNS - Neuroblastoma", "company_us": "US: SERB, EU: SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "First line", "stage": "Phase II", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Sep 2026", "nct_id": "NCT07100704", "ct_url": "https://clinicaltrials.gov/study/NCT07100704", "ct_title": "Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab", "ct_status": "RECRUITING"}, {"name": "Repocarcitin", "tumor": "CNS - Neuroblastoma", "company_us": "US: Novartis, EU: Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase I", "results_date": "Feb 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Gamma-delta-T", "tumor": "CNS - Neuroblastoma", "company_us": "US: Emery, EU: Emery", "company_eu": "Emery", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "gamma T cells", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "NCT05400603", "ct_url": "https://clinicaltrials.gov/study/NCT05400603", "ct_title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "ct_status": "RECRUITING"}, {"name": "Nivolumab", "tumor": "Other", "company_us": "US: Novostei, EU: Novostei", "company_eu": "Novostei", "line": "Fourth line", "stage": "Phase II", "year": 2023.0, "moa": "ALK inhibitor", "tumor_raw": "Lung cancer - NSCLC", "moa_raw": "ALK inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2023", "nct_id": "NCT04136470", "ct_url": "https://clinicaltrials.gov/study/NCT04136470", "ct_title": "BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics", "ct_status": "UNKNOWN"}, {"name": "Tinotrectinib", "tumor": "CNS - Neuroblastoma", "company_us": "US: Medimune, EU: HFYA", "company_eu": "HFYA", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "WJ15129", "tumor": "Solid tumors", "company_us": "US: Junshi Biosciences, EU: Junshi Biosciences", "company_eu": "Junshi Biosciences", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Aurora A inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nivolumab", "tumor": "Solid tumors", "company_us": "US: BMS, EU: BMS", "company_eu": "BMS", "line": "(Neo-)adjuvant", "stage": "Phase II", "year": 2025.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2025", "nct_id": "NCT05601752", "ct_url": "https://clinicaltrials.gov/study/NCT05601752", "ct_title": "ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "HBI 0001", "tumor": "Solid tumors", "company_us": "US: Hadassah Medical, EU: Hadassah Medical", "company_eu": "Hadassah Medical", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "TCR NY-ESO-1", "stage_raw": "Phase II", "results_date": "Dec 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TAAT", "tumor": "Solid tumors", "company_us": "US: Cancer Research, EU: Chabris Research", "company_eu": "Chabris Research", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Multi-TAA specific CTLs", "stage_raw": "Phase I", "results_date": "Oct 2026", "nct_id": "NCT02064647", "ct_url": "https://clinicaltrials.gov/study/NCT02064647", "ct_title": "Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study)", "ct_status": "COMPLETED"}, {"name": "TAAD", "tumor": "Solid tumors", "company_us": "US: BioTherapeutics, EU: PentoRegen BioTherapeutics", "company_eu": "PentoRegen BioTherapeutics", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART CD276", "stage_raw": "Phase I", "results_date": "Dec 2023", "nct_id": "NCT06676371", "ct_url": "https://clinicaltrials.gov/study/NCT06676371", "ct_title": "Total Arch Replacement With Frozen Elephant Trunk Versus Hemiarch Replacement in the Management of Acute Type A Aortic Dissection", "ct_status": "NOT_YET_RECRUITING"}, {"name": "Cibisatamab", "tumor": "Solid tumors", "company_us": "US: Servier, EU: Ipsen", "company_eu": "Ipsen", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "MET, RET, VEGFr, KIT, AXL inhibitor", "stage_raw": "Phase II", "results_date": "Jul 2026", "nct_id": "NCT03866239", "ct_url": "https://clinicaltrials.gov/study/NCT03866239", "ct_title": "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma", "ct_status": "TERMINATED"}, {"name": "GD2-SADA", "tumor": "Solid tumors", "company_us": "US: SERB Pharmaceuticals, EU: SERB Pharmaceuticals", "company_eu": "SERB Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-GD2 I77Lu DOTA fusion protein SADA complex", "stage_raw": "Phase I", "results_date": "Mar 2027", "nct_id": "NCT05130255", "ct_url": "https://clinicaltrials.gov/study/NCT05130255", "ct_title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "ct_status": "RECRUITING"}, {"name": "Rivococlimab", "tumor": "CNS - Neuroblastoma", "company_us": "US: Bayer Therapeutics, EU: Bayer Therapeutics", "company_eu": "Bayer Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "VEGFR-2 inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "VEGFR-2 inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Repodarcitin", "tumor": "Solid tumors", "company_us": "US: BMS, EU: BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Multi-kinase inhibitor", "stage_raw": "Phase II", "results_date": "Aug 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Divoxiximab", "tumor": "CNS - Neuroblastoma", "company_us": "US: Memorial Sloan, EU: Memorial Sloan", "company_eu": "Memorial Sloan", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Jun 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "177Lu-DOTAT-Y10-Octreotate", "tumor": "CNS - Neuroblastoma", "company_us": "US: Novartis, EU: Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-SSTR2 radoconjugate", "stage_raw": "Phase II", "results_date": "May 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imloclicin Nal-01", "tumor": "Solid tumors", "company_us": "US: Servier, EU: Servier", "company_eu": "Servier", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Topoisomerase I inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "Topoisomerase I inhibitor", "stage_raw": "Phase II", "results_date": "May 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Patidegib", "tumor": "Solid tumors", "company_us": "US: pharmaK Schwez, EU: pharmaK Schwez", "company_eu": "pharmaK Schwez", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "HDAC inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2021", "nct_id": "NCT02762084", "ct_url": "https://clinicaltrials.gov/study/NCT02762084", "ct_title": "Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients", "ct_status": "COMPLETED"}, {"name": "BT-474 CART", "tumor": "Solid tumors", "company_us": "US: St. Jude, EU: St. Jude", "company_eu": "St. Jude", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "CART B7-H3", "tumor_raw": "Solid tumors", "moa_raw": "CART B7-H3", "stage_raw": "Phase I", "results_date": "Mar 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CD276-CART", "tumor": "Solid tumors", "company_us": "US: Perkinson, EU: Perkinson BioTherapeutics", "company_eu": "Perkinson BioTherapeutics", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART CD276", "stage_raw": "Early Phase I", "results_date": "May 2022", "nct_id": "NCT04433221", "ct_url": "https://clinicaltrials.gov/study/NCT04433221", "ct_title": "Combination Immunotherapy Targeting Sarcomas", "ct_status": "UNKNOWN"}, {"name": "Tegulimab", "tumor": "Solid tumors", "company_us": "US: Renen, EU: Renen Therapeutics", "company_eu": "Renen Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "TBI-1 inhibitor", "stage_raw": "Phase II", "results_date": "Apr 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Amlodipine", "tumor": "CNS - Neuroblastoma", "company_us": "US: Cida Tail, EU: Cida Tail", "company_eu": "Cida Tail", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "RTK/VEGFr inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2023", "nct_id": "NCT00160212", "ct_url": "https://clinicaltrials.gov/study/NCT00160212", "ct_title": "Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension", "ct_status": "COMPLETED"}, {"name": "L-131-debenguide", "tumor": "CNS - Neuroblastoma", "company_us": "US: Lantheus, EU: Lantheus Holdings", "company_eu": "Lantheus Holdings", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Dec 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lustaxen", "tumor": "CNS - Neuroblastoma", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Phase IV", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK/ROS1 inhibitor", "stage_raw": "Phase IV", "results_date": "Sep 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lentaxen", "tumor": "CNS - Neuroblastoma", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Phase I", "year": 2020.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK/ROS1 inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GD2-CART-GI", "tumor": "CNS - Neuroblastoma", "company_us": "US: Crospdale, EU: Crospdale Barriskey", "company_eu": "Crospdale Barriskey", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase I", "results_date": "Sep 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ICN GD2 CAR IL-15", "tumor": "CNS - Neuroblastoma", "company_us": "US: Lindberger, EU: Lindberger", "company_eu": "Lindberger", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "May 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Patoclasis", "tumor": "Solid tumors", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase II", "results_date": "Aug 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ulixertinib", "tumor": "Solid tumors", "company_us": "US: BioMed Valley, EU: BioMed Valley", "company_eu": "BioMed Valley", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "ERK inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2022", "nct_id": "NCT03155620", "ct_url": "https://clinicaltrials.gov/study/NCT03155620", "ct_title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "C7R-GD2-CART", "tumor": "CNS - Neuroblastoma", "company_us": "US: Baylor, EU: Baylor College", "company_eu": "Baylor College", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART C7R-GD2", "stage_raw": "Phase I", "results_date": "May 2023", "nct_id": "NCT03635632", "ct_url": "https://clinicaltrials.gov/study/NCT03635632", "ct_title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "EGFRvIII-CD19-CART", "tumor": "Solid tumors", "company_us": "US: Searels, EU: Searels Children's", "company_eu": "Searels Children's", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART EGFRvIII-CD19", "stage_raw": "Phase I", "results_date": "Jan 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Elotransib-oral", "tumor": "CNS - Neuroblastoma", "company_us": "US: Otbus, EU: Otbus Therapeutics", "company_eu": "Otbus Therapeutics", "line": "Second line", "stage": "Phase III", "year": 2019.0, "moa": "ODC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ODC inhibitor", "stage_raw": "Phase III", "results_date": "Apr 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "L-131-debenguide", "tumor": "CNS - Neuroblastoma", "company_us": "US: Lanthaus, EU: Lanthaus Holdings", "company_eu": "Lanthaus Holdings", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Dec 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Pcipoloc-ib", "tumor": "Solid tumors", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ipodenone (-13)", "tumor": "Solid tumors", "company_us": "US: Collector, EU: BioSciences", "company_eu": "BioSciences", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Radiopharmaceutical", "tumor_raw": "Solid tumors", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ribociclib", "tumor": "CNS - Glioma", "company_us": "US: Novartis, EU: Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Glioma", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase I", "results_date": "Sep 2022", "nct_id": "NCT03355794", "ct_url": "https://clinicaltrials.gov/study/NCT03355794", "ct_title": "A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)", "ct_status": "COMPLETED"}, {"name": "Aberneacin", "tumor": "Solid tumors", "company_us": "US: Ell Lilly, EU: Ell Lilly", "company_eu": "Ell Lilly", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CDK46 inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GVAX", "tumor": "CNS - Neuroblastoma", "company_us": "US: Cell Genesys, EU: Cell Genesys", "company_eu": "Cell Genesys", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "Mar 2025", "nct_id": "NCT00133224", "ct_url": "https://clinicaltrials.gov/study/NCT00133224", "ct_title": "Docetaxel in Combination With GVAX \u00ae Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients", "ct_status": "TERMINATED"}, {"name": "Elaglucibat", "tumor": "Other", "company_us": "US: Actualis, EU: Actualis Therapeutics", "company_eu": "Actualis Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "Soft Tissue sarcoma (STS)", "moa_raw": "GSK-3p inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NK cells", "tumor": "CNS - Neuroblastoma", "company_us": "US: Nationale, EU: Nationale Children's", "company_eu": "Nationale Children's", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "NK cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NK cells", "stage_raw": "Phase II", "results_date": "May 2024", "nct_id": "NCT01576692", "ct_url": "https://clinicaltrials.gov/study/NCT01576692", "ct_title": "Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Ivasikin", "tumor": "Solid tumors", "company_us": "US: Servior, EU: Servior", "company_eu": "Servior", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "IDH1 inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "EMA Vaccine", "tumor": "CNS - Neuroblastoma", "company_us": "US: NCI, EU: NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Early Phase I", "results_date": "Dec 2023", "nct_id": "NCT00071942", "ct_url": "https://clinicaltrials.gov/study/NCT00071942", "ct_title": "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer", "ct_status": "TERMINATED"}, {"name": "GTC-SRITATTE", "tumor": "CNS - Neuroblastoma", "company_us": "US: Clarity, EU: Clarity Pharmaceuticals", "company_eu": "Clarity Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "SSTR2 radoconjugate", "stage_raw": "Phase II", "results_date": "Sep 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ertintelimab", "tumor": "Solid tumors", "company_us": "US: Ell Lilly, EU: Ell Lilly", "company_eu": "Ell Lilly", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "ALK inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "ALK inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nivolumab", "tumor": "Solid tumors", "company_us": "US: WorldMeds, EU: WorldMeds", "company_eu": "WorldMeds", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Oct 2028", "nct_id": "NCT05601752", "ct_url": "https://clinicaltrials.gov/study/NCT05601752", "ct_title": "ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Tafinla", "tumor": "Solid tumors", "company_us": "US: Kara Oncology, EU: Kara Oncology", "company_eu": "Kara Oncology", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Farnesyl transferase inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ICI9 GD2 CAR IL-15", "tumor": "CNS - Neuroblastoma", "company_us": "US: Lindberger, EU: Lindberger", "company_eu": "Lindberger", "line": "Second line", "stage": "Phase I", "year": 2030.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "May 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ilersarib", "tumor": "Solid tumors", "company_us": "US: Xonvey, EU: Xonvey", "company_eu": "Xonvey", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "ALK inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "ALK inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Lordanim", "tumor": "CNS - Neuroblastoma", "company_us": "US: Pfizer, EU: Pfizer", "company_eu": "Pfizer", "line": "First line", "stage": "Phase III", "year": 2030.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK/ROS1 inhibitor", "stage_raw": "Phase III", "results_date": "Sep 2030", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "90Y-DOTA-TOC", "tumor": "Neuroendocrine tumors", "company_us": "US: University of, EU: University of", "company_eu": "University of", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Neuroendocrine tumors", "moa_raw": "90Y-DOTA-TOC", "stage_raw": "Phase II", "results_date": "Aug 2017", "nct_id": "NCT00978211", "ct_url": "https://clinicaltrials.gov/study/NCT00978211", "ct_title": "DOTA-TOC in Metastasized Neuroendocrine Tumors", "ct_status": "COMPLETED"}, {"name": "Racimorumab", "tumor": "CNS - Neuroblastoma", "company_us": "US: Euderma, EU: Euderma", "company_eu": "Euderma", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-P3 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Nov 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eculizumab", "tumor": "Solid tumors", "company_us": "US: MacroGenics, EU: MacroGenics", "company_eu": "MacroGenics", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-B7-H3 monoclonal antibody", "stage_raw": "Phase I", "results_date": "May 2019", "nct_id": "NCT04320602", "ct_url": "https://clinicaltrials.gov/study/NCT04320602", "ct_title": "Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab", "ct_status": "COMPLETED"}, {"name": "GD2-CART", "tumor": "CNS - Neuroblastoma", "company_us": "US: Sincell Biology, EU: Sincell Biology", "company_eu": "Sincell Biology", "line": "Second line", "stage": "Phase I", "year": 2020.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Sep 2020", "nct_id": "NCT02761915", "ct_url": "https://clinicaltrials.gov/study/NCT02761915", "ct_title": "A Phase I Trial of Anti-GD2 T-cells (1RG-CART)", "ct_status": "COMPLETED"}, {"name": "TAAL-CTL3", "tumor": "Solid tumors", "company_us": "US: Children's National, EU: Children's National", "company_eu": "Children's National", "line": "Second line", "stage": "Phase I", "year": 2020.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "MultiTAA specific CTLs", "stage_raw": "Phase I", "results_date": "Sep 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Cimiterbo", "tumor": "CNS - Neuroblastoma", "company_us": "US: Novartis, EU: Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2018.0, "moa": "ALK inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK inhibitor", "stage_raw": "Phase I", "results_date": "May 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Certolizumab", "tumor": "CNS - Neuroblastoma", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2016.0, "moa": "ALK inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK inhibitor", "stage_raw": "Phase I", "results_date": "May 2016", "nct_id": "NCT01691014", "ct_url": "https://clinicaltrials.gov/study/NCT01691014", "ct_title": "Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents", "ct_status": "TERMINATED"}, {"name": "Ribociclib", "tumor": "CNS - Neuroblastoma", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CDK4/6 inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2023", "nct_id": "NCT03434262", "ct_url": "https://clinicaltrials.gov/study/NCT03434262", "ct_title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "ct_status": "COMPLETED"}, {"name": "Trametsib", "tumor": "CNS - Neuroblastoma", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "MEK inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ASCT", "tumor": "CNS - Neuroblastoma", "company_us": "King Hussein", "company_eu": "King Hussein", "line": "First line", "stage": "Phase II", "year": 2020.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Autologous stem cells transplantation", "stage_raw": "Phase II", "results_date": "Mar 2020", "nct_id": "NCT03786783", "ct_url": "https://clinicaltrials.gov/study/NCT03786783", "ct_title": "Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "AUTO6", "tumor": "CNS - Neuroblastoma", "company_us": "Autolus", "company_eu": "Autolus Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2018.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Apr 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Dinutuximab beta", "tumor": "CNS - Neuroblastoma", "company_us": "Roche", "company_eu": "Roche", "line": "Fourth line", "stage": "Phase II", "year": 2023.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jun 2023", "nct_id": "NCT04221035", "ct_url": "https://clinicaltrials.gov/study/NCT04221035", "ct_title": "High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)", "ct_status": "RECRUITING"}, {"name": "Floriflucan oral", "tumor": "CNS - Neuroblastoma", "company_us": "Orbus", "company_eu": "Orbus Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2028.0, "moa": "ODC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ODC inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Entrectinib", "tumor": "Solid tumors", "company_us": "Genentech", "company_eu": "Roche", "line": "Second line", "stage": "Approved", "year": 2018.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "NTRK, ROS1, ALK inhibitor", "stage_raw": "Approved", "results_date": "Jun 2018", "nct_id": "NCT02650401", "ct_url": "https://clinicaltrials.gov/study/NCT02650401", "ct_title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Anemacicib", "tumor": "CNS - Glioma", "company_us": "Eli Lilly", "company_eu": "Eli Lilly", "line": "First line", "stage": "Phase I", "year": 2018.0, "moa": "Other", "tumor_raw": "CNS - Glioma", "moa_raw": "NTRK, ROS1, ALK inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Cobimetanib", "tumor": "Solid tumors", "company_us": "Genentech", "company_eu": "Roche", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CDK4/6 inhibitor", "stage_raw": "Phase II", "results_date": "Oct 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Entrectinib", "tumor": "CNS - Neuroblastoma", "company_us": "Denovo", "company_eu": "Denovo Biopharma", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Recombinant human endostatin", "stage_raw": "Phase II", "results_date": "Nov 2017", "nct_id": "NCT02650401", "ct_url": "https://clinicaltrials.gov/study/NCT02650401", "ct_title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Endostatins", "tumor": "CNS - Neuroblastoma", "company_us": "Genentech", "company_eu": "Roche", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Recombinant human endostatin", "stage_raw": "Phase II", "results_date": "Nov 2017", "nct_id": "NCT02615106", "ct_url": "https://clinicaltrials.gov/study/NCT02615106", "ct_title": "Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma", "ct_status": "UNKNOWN"}, {"name": "Alectinumab", "tumor": "Solid tumors", "company_us": "Genentech", "company_eu": "Roche", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-L1 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jun 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NY-ESO-1 TCR", "tumor": "Solid tumors", "company_us": "Shenzhen Sinocan", "company_eu": "Shenzhen Sinocan", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "TCR NY-ESO-1", "stage_raw": "Phase I", "results_date": "Dec 2019", "nct_id": "NCT03691376", "ct_url": "https://clinicaltrials.gov/study/NCT03691376", "ct_title": "Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "ct_status": "TERMINATED"}, {"name": "Alicertib", "tumor": "Solid tumors", "company_us": "Puma Biotechnology", "company_eu": "Puma Biotechnology", "line": "Second line", "stage": "Phase I", "year": 2011.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Aurora A kinase inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "66Ga-Eoteotide (Doea)", "tumor": "Neuroendocrine tumors", "company_us": "University of", "company_eu": "University of", "line": "First line", "stage": "Phase II", "year": 2020.0, "moa": "Other", "tumor_raw": "Neuroendocrine tumors", "moa_raw": "SST R2", "stage_raw": "Phase II", "results_date": "Jan 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eftinisuma", "tumor": "CNS - Neuroblastoma", "company_us": "US Worldwidel", "company_eu": "Norgren", "line": "Second line", "stage": "Approved", "year": 2022.0, "moa": "ODC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ODC inhibitor", "stage_raw": "Approved", "results_date": "Jun 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "JCAR593", "tumor": "CNS - Neuroblastoma", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "ODC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ODC inhibitor", "stage_raw": "Phase I", "results_date": "Nov 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nivolumab", "tumor": "Solid tumors", "company_us": "BMS", "company_eu": "BMS", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART L1 CAM", "stage_raw": "Phase II", "results_date": "Jan 2017", "nct_id": "NCT05601752", "ct_url": "https://clinicaltrials.gov/study/NCT05601752", "ct_title": "ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Sorafenib", "tumor": "CNS - Neuroblastoma", "company_us": "Bayer", "company_eu": "Bayer", "line": "Second line", "stage": "Phase I", "year": 2017.0, "moa": "Anti-PD-1 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-PD-1 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Jan 2017", "nct_id": "NCT01518413", "ct_url": "https://clinicaltrials.gov/study/NCT01518413", "ct_title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors", "ct_status": "COMPLETED"}, {"name": "GD2-B-ATC", "tumor": "CNS - Neuroblastoma", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Multikinase inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "nrf1-186/22A", "tumor": "Soft tissue sarcoma (STS)", "company_us": "Pharma", "company_eu": "Pharma", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Anti-3F8/KCD3 bispecific antibody armed ATC", "stage_raw": "Phase I", "results_date": "Oct 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eftinisuma oral", "tumor": "CNS - Neuroblastoma", "company_us": "Ortus Therapeutics", "company_eu": "Ortus Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "ODC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ODC inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CD133+ cells", "tumor": "CNS - Neuroblastoma", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2017.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CD133+ autologous stem cells", "stage_raw": "Phase I", "results_date": "Dec 2017", "nct_id": "NCT00539500", "ct_url": "https://clinicaltrials.gov/study/NCT00539500", "ct_title": "Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma", "ct_status": "TERMINATED"}, {"name": "Dabrafenib", "tumor": "Solid tumors", "company_us": "Novartis", "company_eu": "Novartis", "line": "Second line", "stage": "Approved", "year": 2018.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "BRAF inhibitor", "stage_raw": "Approved", "results_date": "Jun 2018", "nct_id": "NCT01072175", "ct_url": "https://clinicaltrials.gov/study/NCT01072175", "ct_title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212", "ct_status": "COMPLETED"}, {"name": "GD2/GM2/CD28 CART", "tumor": "CNS - Neuroblastoma", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Apr 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NK Cells", "tumor": "Solid tumors", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase II", "year": 2020.0, "moa": "Natural Killer Cells", "tumor_raw": "Solid tumors", "moa_raw": "Natural Killer Cells", "stage_raw": "Phase II", "results_date": "Dec 2020", "nct_id": "NCT01915992", "ct_url": "https://clinicaltrials.gov/study/NCT01915992", "ct_title": "Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies", "ct_status": "UNKNOWN"}, {"name": "3F8", "tumor": "CNS - Neuroblastoma", "company_us": "MSKCC", "company_eu": "MSKCC", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Mar 2019", "nct_id": "NCT00450307", "ct_url": "https://clinicaltrials.gov/study/NCT00450307", "ct_title": "Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "I-131 adrenoguanide", "tumor": "CNS - Neuroblastoma", "company_us": "Lantheud Holdings", "company_eu": "Lantheud Holdings", "line": "Second line", "stage": "Phase II", "year": 2020.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Jan 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eftinisuma sachets", "tumor": "CNS - Neuroblastoma", "company_us": "Parsidea Therapeutics", "company_eu": "Parsidea Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2024.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Jan 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imbruvicin Mab-iBT", "tumor": "Solid tumors", "company_us": "Serum", "company_eu": "Serum", "line": "Second line", "stage": "Phase I", "year": 2017.0, "moa": "ODC inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "ODC inhibitor", "stage_raw": "Phase I", "results_date": "Apr 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imbiresoni", "tumor": "Solid tumors", "company_us": "Geron", "company_eu": "Geron", "line": "Second line", "stage": "Phase II", "year": 2016.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Telomerase inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BC-GD2 CART", "tumor": "Soft tissue sarcoma (STS)", "company_us": "Marker Therapeutics", "company_eu": "Marker Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2019.0, "moa": "Other", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "CXC14 antagonist", "stage_raw": "Phase I", "results_date": "Feb 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Imbiresoni", "tumor": "CNS - Neuroblastoma", "company_us": "Geron", "company_eu": "Geron", "line": "Second line", "stage": "Phase I", "year": 2013.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Telomerase inhibitor", "stage_raw": "Phase I", "results_date": "Nov 2013", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "RRL-15", "tumor": "Solid tumors", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2015.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Recombinant IL-15", "stage_raw": "Phase I", "results_date": "Sep 2015", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BRGs-Eoteotide (Ivey)", "tumor": "Solid tumors", "company_us": "University of", "company_eu": "University of", "line": "First line", "stage": "Phase II", "year": 2018.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "SST R2 radioconjugate", "stage_raw": "Phase II", "results_date": "Dec 2018", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Frif14 186/22A", "tumor": "CNS - Neuroblastoma", "company_us": "Essential Pharma", "company_eu": "Essential Pharma", "line": "First line", "stage": "Phase II", "year": 2017.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Jul 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "I-131-adrenoguanide", "tumor": "CNS - Neuroblastoma", "company_us": "Lantheud Holdings", "company_eu": "Lantheud Holdings", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BCD-245", "tumor": "CNS - Neuroblastoma", "company_us": "Biocar", "company_eu": "Biocar", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2026", "nct_id": "NCT05782959", "ct_url": "https://clinicaltrials.gov/study/NCT05782959", "ct_title": "Phase 1 Study of BCD-245 in Subjects With Neuroblastoma", "ct_status": "UNKNOWN"}, {"name": "Instaran", "tumor": "CNS - Neuroblastoma", "company_us": "Atheneum", "company_eu": "Atheneum", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "mTORC1-1mTORC2/3-mFR", "stage_raw": "Phase II", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "17Flu-Coxarboxine", "tumor": "CNS - Neuroblastoma", "company_us": "Sinotau Pharmaceuticals", "company_eu": "Sinotau Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-SST R2 radioconjugate", "stage_raw": "Phase I", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "VNX-201", "tumor": "CNS - Neuroblastoma", "company_us": "Viventes Biotherapeutics", "company_eu": "Viventes Biotherapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "AAV gene therapy", "stage_raw": "Preclinical", "results_date": "Sep 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Ipilimumab", "tumor": "Other", "company_us": "BMS", "company_eu": "BMS", "line": "First line", "stage": "Approved", "year": 2012.0, "moa": "Other", "tumor_raw": "Melanoma", "moa_raw": "Anti-CTLA-4 monoclonal antibody", "stage_raw": "Approved", "results_date": "Jun 2012", "nct_id": "NCT02381314", "ct_url": "https://clinicaltrials.gov/study/NCT02381314", "ct_title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer", "ct_status": "COMPLETED"}, {"name": "Olapatu", "tumor": "CNS - Neuroblastoma", "company_us": "AstraZeneca", "company_eu": "AstraZeneca", "line": "Second line", "stage": "Phase I", "year": 2014.0, "moa": "PARP inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "PARP inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2014", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "APN301", "tumor": "CNS - Neuroblastoma", "company_us": "Apeiron Biologics", "company_eu": "Apeiron Biologics", "line": "Third line", "stage": "Phase II", "year": 2015.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "anti-GD2/IL-2 fusion protein", "stage_raw": "Phase II", "results_date": "Jun 2015", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Picibanil", "tumor": "Solid tumors", "company_us": "Rancl", "company_eu": "Rancl", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CXC14 antagonist", "stage_raw": "Phase II", "results_date": "May 2017", "nct_id": "NCT01699347", "ct_url": "https://clinicaltrials.gov/study/NCT01699347", "ct_title": "Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432", "ct_status": "UNKNOWN"}, {"name": "DC vaccine", "tumor": "CNS - Neuroblastoma", "company_us": "Trickson Biotherapeutics", "company_eu": "Trickson Biotherapeutics", "line": "Second line", "stage": "Phase I", "year": 2014.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "May 2014", "nct_id": "NCT02745756", "ct_url": "https://clinicaltrials.gov/study/NCT02745756", "ct_title": "A Combined Cell Therapy Approach to the Treatment of Neuroblastoma", "ct_status": "WITHDRAWN"}, {"name": "Neuroblastoma vaccine", "tumor": "CNS - Neuroblastoma", "company_us": "Baylor College", "company_eu": "Baylor College", "line": "Second line", "stage": "Phase II", "year": 2012.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Jul 2012", "nct_id": "NCT00186862", "ct_url": "https://clinicaltrials.gov/study/NCT00186862", "ct_title": "Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Pearlicadoptric", "tumor": "Solid tumors", "company_us": "Transgenicl", "company_eu": "Transgenicl", "line": "Second line", "stage": "Phase I", "year": 2015.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Oncolytic virus", "stage_raw": "Phase I", "results_date": "Jan 2015", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Aiscerb", "tumor": "Solid tumors", "company_us": "Puma Biotechnology", "company_eu": "Puma Biotechnology", "line": "Second line", "stage": "Phase II", "year": 2019.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Aurora A kinase inhibitor", "stage_raw": "Phase II", "results_date": "Feb 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Vorinostat", "tumor": "Solid tumors", "company_us": "Merck", "company_eu": "MSD", "line": "Second line", "stage": "Phase I", "year": 2011.0, "moa": "HDAC inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2011", "nct_id": "NCT00336063", "ct_url": "https://clinicaltrials.gov/study/NCT00336063", "ct_title": "Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Somilactin", "tumor": "Other", "company_us": "Sun Pharmaceutical", "company_eu": "Sun Pharmaceutical", "line": "Second line", "stage": "Phase II", "year": 2012.0, "moa": "Other", "tumor_raw": "CNS - Medulloblastoma", "moa_raw": "SMO inhibitor", "stage_raw": "Phase II", "results_date": "Jun 2012", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Vorinosat", "tumor": "CNS - Neuroblastoma", "company_us": "Merck", "company_eu": "MSD", "line": "Second line", "stage": "Phase I", "year": 2014.0, "moa": "HDAC inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2014", "nct_id": "NCT04308330", "ct_url": "https://clinicaltrials.gov/study/NCT04308330", "ct_title": "Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies", "ct_status": "UNKNOWN"}, {"name": "Pembrolizumab", "tumor": "Neuroendocrine tumors", "company_us": "Genentech", "company_eu": "Roche", "line": "First line", "stage": "Phase II", "year": 2010.0, "moa": "Other", "tumor_raw": "Neuroendocrine tumors", "moa_raw": "Anti-HER-2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "May 2010", "nct_id": "NCT03582475", "ct_url": "https://clinicaltrials.gov/study/NCT03582475", "ct_title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Critreutin", "tumor": "Other", "company_us": "Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Approved", "year": 2012.0, "moa": "Other", "tumor_raw": "NHL - PTCL", "moa_raw": "C-MET, ALK, ROS1 inhibitor", "stage_raw": "Approved", "results_date": "Jun 2012", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Critreutin", "tumor": "Other", "company_us": "Pfizer", "company_eu": "Pfizer", "line": "Second line", "stage": "Approved", "year": 2012.0, "moa": "Other", "tumor_raw": "Other", "moa_raw": "C-MET, ALK, ROS1 inhibitor", "stage_raw": "Approved", "results_date": "Jun 2012", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CYT107", "tumor": "CNS - Neuroblastoma", "company_us": "Revimmune", "company_eu": "Revimmune", "line": "Second line", "stage": "Phase II", "year": 2012.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "rIL-7", "stage_raw": "Phase II", "results_date": "Aug 2012", "nct_id": "NCT00923351", "ct_url": "https://clinicaltrials.gov/study/NCT00923351", "ct_title": "Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "TFH 207", "tumor": "CNS - Neuroblastoma", "company_us": "Cortico Biosciences", "company_eu": "Cortico Biosciences", "line": "Second line", "stage": "Phase I", "year": 2011.0, "moa": "Microtubule inhibitor", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Microtubule inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "31C-Melthipugo", "tumor": "CNS - Glioma", "company_us": "St. Jude", "company_eu": "St. Jude", "line": "First line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Glioma", "moa_raw": "Amino acid radioconjugate", "stage_raw": "Phase II", "results_date": "Jul 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "SMNF-II-151 en", "tumor": "CNS - Neuroblastoma", "company_us": "Baylor College of Medicine", "company_eu": "Baylor College of Medicine", "line": "Second line", "stage": "Phase II", "year": 2011.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "May 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Vorinosat", "tumor": "Solid tumors", "company_us": "Merck", "company_eu": "MSD", "line": "Second line", "stage": "Phase I", "year": 2009.0, "moa": "HDAC inhibitor", "tumor_raw": "Solid tumors", "moa_raw": "HDAC inhibitor", "stage_raw": "Phase I", "results_date": "Sep 2009", "nct_id": "NCT04308330", "ct_url": "https://clinicaltrials.gov/study/NCT04308330", "ct_title": "Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies", "ct_status": "UNKNOWN"}, {"name": "EBV-CTL", "tumor": "CNS - Neuroblastoma", "company_us": "Baylor College", "company_eu": "Baylor College", "line": "Second line", "stage": "Phase I", "year": 2010.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "EBV-specific CTLs", "stage_raw": "Phase I", "results_date": "Jan 2010", "nct_id": "NCT00085930", "ct_url": "https://clinicaltrials.gov/study/NCT00085930", "ct_title": "Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients", "ct_status": "COMPLETED"}, {"name": "APN201", "tumor": "CNS - Neuroblastoma", "company_us": "Apeiron Biologics", "company_eu": "Apeiron Biologics", "line": "Second line", "stage": "Phase II", "year": 2010.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "anti-GD2/IL-2 fusion protein", "stage_raw": "Phase II", "results_date": "Nov 2010", "nct_id": "NCT01513278", "ct_url": "https://clinicaltrials.gov/study/NCT01513278", "ct_title": "Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer", "ct_status": "COMPLETED"}, {"name": "LCH03", "tumor": "Other", "company_us": "NCI", "company_eu": "NCI", "line": "Second line", "stage": "Phase I", "year": 2012.0, "moa": "Other", "tumor_raw": "Breast cancer - TN", "moa_raw": "AM inhibitor", "stage_raw": "Phase I", "results_date": "Jun 2012", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "WT1 cancer vaccine", "tumor": "Soft tissue sarcoma (STS)", "company_us": "University of Osaka", "company_eu": "University of Osaka", "line": "First line", "stage": "Phase II", "year": 2012.0, "moa": "Cancer vaccine", "tumor_raw": "Soft tissue sarcoma (STS)", "moa_raw": "Cancer vaccine", "stage_raw": "Phase II", "results_date": "Aug 2012", "nct_id": "NCT00509691", "ct_url": "https://clinicaltrials.gov/study/NCT00509691", "ct_title": "Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy", "ct_status": "COMPLETED"}, {"name": "ET509", "tumor": "Neuroendocrine tumors", "company_us": "Psicoaction Therapeutics", "company_eu": "Psicoaction Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "Neuroendocrine tumors", "moa_raw": "TBD", "stage_raw": "Preclinical", "results_date": "Feb 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Deniketotide", "tumor": "Solid tumors", "company_us": "Jazz Pharmaceuticals", "company_eu": "Jazz Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "DRD2 antagonist", "stage_raw": "Phase I", "results_date": "Sep 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Cyclophosphamide", "tumor": "Solid tumors", "company_us": "Neopharm", "company_eu": "Neopharm", "line": "Second line", "stage": "Approved", "year": 2022.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Alkylating agent", "stage_raw": "Approved", "results_date": "Aug 2022", "nct_id": "NCT02465801", "ct_url": "https://clinicaltrials.gov/study/NCT02465801", "ct_title": "Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein", "ct_status": "COMPLETED"}, {"name": "AUT-ZXX", "tumor": "Solid tumors", "company_us": "Autolus Therapeutics", "company_eu": "Autolus Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Undisclosed", "stage_raw": "Preclinical", "results_date": "Sep 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "AM66901", "tumor": "Other", "company_us": "Amtomax Pharamaceuticls", "company_eu": "Amtomax Pharamaceuticls", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "ALK inhibitor", "tumor_raw": "NHL - PTCL", "moa_raw": "ALK inhibitor", "stage_raw": "Preclinical", "results_date": "Jan 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Naxitamab", "tumor": "Solid tumors", "company_us": "Eufarma Laboratorios", "company_eu": "Eufarma Laboratorios", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "Solid tumors", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2017", "nct_id": "NCT03033303", "ct_url": "https://clinicaltrials.gov/study/NCT03033303", "ct_title": "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "Naciumab", "tumor": "Solid tumors", "company_us": "Nascent Laboratories", "company_eu": "Nascent Laboratories", "line": "Second line", "stage": "Phase II", "year": 2017.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-P3 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2017", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Tembadone", "tumor": "Solid tumors", "company_us": "Nestos", "company_eu": "Nestos EU Tmec", "line": "Second line", "stage": "Phase II", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "RARB agonist", "stage_raw": "Phase II", "results_date": "Nov 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LX-10", "tumor": "Solid tumors", "company_us": "US Lineum Therapeutics", "company_eu": "EU Lineum Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "IGF-methotrexate conjugate", "stage_raw": "Phase I", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "D3-GPC2-FRO", "tumor": "CNS - Neuroblastoma", "company_us": "US Children's Hospital", "company_eu": "EU Children's Hospital", "line": "Preclinical", "stage": "Preclinical", "year": 2020.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GPC2 ADC monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Feb 2020", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "AUTGMC2", "tumor": "CNS - Neuroblastoma", "company_us": "US Autolus", "company_eu": "EU Autolus Therapeutics", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Jun 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "MVT-GD2", "tumor": "CNS - Neuroblastoma", "company_us": "US BioNTech", "company_eu": "EU BioNTech", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Jul 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "SACT-1", "tumor": "CNS - Neuroblastoma", "company_us": "US Lentio", "company_eu": "EU Astronix", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "MYCN inhibitor", "stage_raw": "Phase II", "results_date": "Sep 2025", "nct_id": "NCT05358756", "ct_url": "https://clinicaltrials.gov/study/NCT05358756", "ct_title": "A Study of Bioavailability and Food Effect of SACT-1 and Edurant\u00ae Tablets in Healthy Adult Volunteers", "ct_status": "COMPLETED"}, {"name": "BZ76-FHD", "tumor": "CNS - Neuroblastoma", "company_us": "US MD Biosciences", "company_eu": "EU MD Biosciences", "line": "Preclinical", "stage": "Preclinical", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-B7-H3 ADC monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Nexitamab", "tumor": "CNS - Neuroblastoma", "company_us": "US SERB Pharmaceuticals", "company_eu": "EU SERB Pharmaceuticals", "line": "First line", "stage": "Phase II", "year": 2019.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2019", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Eltragiab", "tumor": "CNS - Neuroblastoma", "company_us": "US Articae Therapeutics", "company_eu": "EU Articae Therapeutics", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "GSK-3b inhibitor", "stage_raw": "Phase II", "results_date": "Mar 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LDC-DKTX", "tumor": "CNS - Neuroblastoma", "company_us": "US Lead Discovery", "company_eu": "EU Lead Discovery", "line": "Preclinical", "stage": "Preclinical", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Undisclosed", "stage_raw": "Preclinical", "results_date": "Nov 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "MDD5", "tumor": "CNS - Neuroblastoma", "company_us": "US University of", "company_eu": "EU University of", "line": "Preclinical", "stage": "Preclinical", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "SMO inhibitor", "stage_raw": "Preclinical", "results_date": "Mar 2022", "nct_id": "NCT03388177", "ct_url": "https://clinicaltrials.gov/study/NCT03388177", "ct_title": "Yoga for Young Women With Depression", "ct_status": "UNKNOWN"}, {"name": "AEBR-MTGN", "tumor": "CNS - Neuroblastoma", "company_us": "US Children's Hospital", "company_eu": "EU Children's Hospital", "line": "Preclinical", "stage": "Preclinical", "year": 2024.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "MYCN degrader", "stage_raw": "Preclinical", "results_date": "Mar 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "JOADH-PROTAC", "tumor": "CNS - Neuroblastoma", "company_us": "US St. Jude", "company_eu": "EU St. Jude", "line": "Preclinical", "stage": "Preclinical", "year": 2024.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "EP300 degrader", "stage_raw": "Preclinical", "results_date": "Nov 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Altonitumab", "tumor": "CNS - Neuroblastoma", "company_us": "US Acetantage Pharma", "company_eu": "EU Acetantage Pharma", "line": "Second line", "stage": "Phase II", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "MiRAP p53 inhibitor", "stage_raw": "Phase II", "results_date": "Dec 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GAIA-102 (iv)", "tumor": "CNS - Neuroblastoma", "company_us": "US GAIA BioMedicine", "company_eu": "EU GAIA BioMedicine", "line": "Second line", "stage": "Phase I", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "PRMC-derived NK-like cells", "stage_raw": "Phase I", "results_date": "Dec 2025", "nct_id": "NCT05608148", "ct_url": "https://clinicaltrials.gov/study/NCT05608148", "ct_title": "Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors", "ct_status": "RECRUITING"}, {"name": "MI-50", "tumor": "CNS - Neuroblastoma", "company_us": "US St. Johns", "company_eu": "EU St. Johns", "line": "Preclinical", "stage": "Preclinical", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Meiun inhibitor", "stage_raw": "Preclinical", "results_date": "Apr 2025", "nct_id": "NCT02272023", "ct_url": "https://clinicaltrials.gov/study/NCT02272023", "ct_title": "Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women", "ct_status": "COMPLETED"}, {"name": "PLB-032256", "tumor": "CNS - Neuroblastoma", "company_us": "US University of", "company_eu": "EU University of", "line": "Preclinical", "stage": "Preclinical", "year": 2024.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "N-Myc degrader", "stage_raw": "Preclinical", "results_date": "Apr 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Topirapalov", "tumor": "CNS - Neuroblastoma", "company_us": "US Delcath", "company_eu": "EU Delcath", "line": "Second line", "stage": "Phase II", "year": 2015.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "N-Myc degrader", "stage_raw": "Phase II", "results_date": "Sep 2015", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Figarabin", "tumor": "CNS - Neuroblastoma", "company_us": "US Dong A ST", "company_eu": "EU Dong A ST", "line": "Second line", "stage": "Phase II", "year": 2016.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "G-CSF", "stage_raw": "Phase II", "results_date": "May 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "ASCT", "tumor": "CNS - Neuroblastoma", "company_us": "US King Heisman", "company_eu": "EU King Heisman", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Autologous stem cells transplantation", "stage_raw": "Phase II", "results_date": "Jul 2022", "nct_id": "NCT03786783", "ct_url": "https://clinicaltrials.gov/study/NCT03786783", "ct_title": "Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Pelledoxius", "tumor": "CNS - Neuroblastoma", "company_us": "US Me University", "company_eu": "EU Me University", "line": "First line", "stage": "Phase I", "year": 2011.0, "moa": "Cancer vaccine", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer vaccine", "stage_raw": "Phase I", "results_date": "Dec 2011", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "4SCAB-GD2 Combination", "tumor": "CNS - Neuroblastoma", "company_us": "US Shenzhen Gene Immune", "company_eu": "EU Shenzhen Gene Immune", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Phase I", "results_date": "Dec 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "AgRx2-4P Combination", "tumor": "CNS - Neuroblastoma", "company_us": "US University of", "company_eu": "EU University of", "line": "Preclinical", "stage": "Preclinical", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Cancer Vaccine", "stage_raw": "Preclinical", "results_date": "Nov 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Sepulieuron Isotude (Cornera)", "tumor": "CNS - Neuroblastoma", "company_us": "US Bioforce Bioscience", "company_eu": "EU Corbera", "line": "Second line", "stage": "Phase I", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "MYCN inhibitor", "stage_raw": "Phase I", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "FLT3P2", "tumor": "CNS - Neuroblastoma", "company_us": "US Eureka Therapeutics", "company_eu": "EU Eureka Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GPC2", "stage_raw": "Preclinical", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Glunumab-delta", "tumor": "CNS - Neuroblastoma", "company_us": "US Recordati", "company_eu": "EU Recordati", "line": "Second line", "stage": "Phase I", "year": 2016.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase I", "results_date": "Jun 2016", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "TREURX-02", "tumor": "CNS - Neuroblastoma", "company_us": "US Tmunity Therapeutics", "company_eu": "EU Tmunity Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2025.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GPC2", "stage_raw": "Preclinical", "results_date": "Jun 2025", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LQZ-7", "tumor": "CNS - Neuroblastoma", "company_us": "US University Children's", "company_eu": "EU University Children's", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "BIRC5/Survivin inhibition", "stage_raw": "Preclinical", "results_date": "Apr 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "B614-1362328", "tumor": "CNS - Neuroblastoma", "company_us": "US Essential Pharma", "company_eu": "EU Essential Pharma", "line": "First line", "stage": "Phase III", "year": 2029.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase III", "results_date": "Jun 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "17FL-DOTA3-hv2 Orbitals", "tumor": "CNS - Neuroblastoma", "company_us": "US Novartis", "company_eu": "EU Novartis", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-SSTR2 radioconjugate", "stage_raw": "Phase II", "results_date": "Mar 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Naxi-Lamab Gyrenasab", "tumor": "CNS - Neuroblastoma", "company_us": "US SERB Pharmaceuticals", "company_eu": "EU SERB Pharmaceuticals", "line": "Second line", "stage": "Phase IV", "year": 2023.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase IV", "results_date": "Oct 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "GD7-540A", "tumor": "CNS - Neuroblastoma", "company_us": "US SERB Pharmaceuticals", "company_eu": "EU SERB Pharmaceuticals", "line": "Second line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2-171u-DOTA fusion protein SADA complex", "stage_raw": "Phase I", "results_date": "Mar 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "IA3-D-G14.16", "tumor": "CNS - Neuroblastoma", "company_us": "US UAC", "company_eu": "EU UAC", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Jul 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "RD3", "tumor": "CNS - Neuroblastoma", "company_us": "US University of", "company_eu": "EU University of", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Oncolytic peptide", "stage_raw": "Preclinical", "results_date": "Apr 2027", "nct_id": "NCT04674514", "ct_url": "https://clinicaltrials.gov/study/NCT04674514", "ct_title": "APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma", "ct_status": "UNKNOWN"}, {"name": "NYC-TGFb", "tumor": "CNS - Neuroblastoma", "company_us": "US EU", "company_eu": "EU", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "TGFbI NK", "stage_raw": "Preclinical", "results_date": "Apr 2027", "nct_id": "NCT02937272", "ct_url": "https://clinicaltrials.gov/study/NCT02937272", "ct_title": "A Study of LY3200882 in Participants With Solid Tumors", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "Lorataxib", "tumor": "CNS - Neuroblastoma", "company_us": "US Pfizer", "company_eu": "EU Pfizer", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "ALK/ROS1 inhibitor", "stage_raw": "Phase II", "results_date": "May 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NRK-Cell", "tumor": "CNS - Neuroblastoma", "company_us": "US Kian Kanetix", "company_eu": "EU Kian Immune", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "NK cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NK cells", "stage_raw": "Phase II", "results_date": "Aug 2026", "nct_id": "NCT01994720", "ct_url": "https://clinicaltrials.gov/study/NCT01994720", "ct_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]", "ct_status": "COMPLETED"}, {"name": "17FL-Linethous Holdings", "tumor": "CNS - Neuroblastoma", "company_us": "US Linethous Holdings", "company_eu": "EU Linethous Holdings", "line": "Second line", "stage": "Phase II", "year": 2022.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "1-131-iobenguane", "tumor": "CNS - Neuroblastoma", "company_us": "US Linethous Holdings", "company_eu": "EU Linethous Holdings", "line": "First line", "stage": "Phase I", "year": 2023.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Sep 2023", "nct_id": "NCT00253435", "ct_url": "https://clinicaltrials.gov/study/NCT00253435", "ct_title": "N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma", "ct_status": "COMPLETED"}, {"name": "1311-iobenguane Combination", "tumor": "CNS - Neuroblastoma", "company_us": "US Linethous Holdings", "company_eu": "EU Linethous Holdings", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Sep 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "BCD-246 Combination", "tumor": "CNS - Neuroblastoma", "company_us": "US BioGad", "company_eu": "EU BioGad", "line": "Second line", "stage": "Phase II", "year": 2026.0, "moa": "Anti-GD2 monoclonal antibody", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2 monoclonal antibody", "stage_raw": "Phase II", "results_date": "Dec 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "1311-iobenguane", "tumor": "CNS - Neuroblastoma", "company_us": "US Linethous Holdings", "company_eu": "EU Linethous Holdings", "line": "First line", "stage": "Phase II", "year": 2022.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "177LU-DOTA3 hv2 Orbitals", "tumor": "CNS - Neuroblastoma", "company_us": "US Novartis", "company_eu": "EU Novartis", "line": "Second line", "stage": "Phase I", "year": 2022.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-SSTR2 radioconjugate", "stage_raw": "Phase I", "results_date": "Oct 2022", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "VNX-201", "tumor": "CNS - Neuroblastoma", "company_us": "US Viriousax Biotherapeutics", "company_eu": "EU Viriousax Biotherapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "AAV gene therapy", "stage_raw": "Preclinical", "results_date": "Sep 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "1-121-iobenguane", "tumor": "CNS - Neuroblastoma", "company_us": "US Linethous Holdings", "company_eu": "EU Linethous Holdings", "line": "Second line", "stage": "Phase II", "year": 2021.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase II", "results_date": "Oct 2021", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "177LU-DOTA3-hv2 Orbitals", "tumor": "CNS - Neuroblastoma", "company_us": "US Novartis", "company_eu": "EU Novartis", "line": "Second line", "stage": "Preclinical", "year": 2029.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2/CD3 bifunctional bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Apr 2029", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LP-X1", "tumor": "CNS - Neuroblastoma", "company_us": "US LantheusBioMedicine", "company_eu": "EU LantheusBioMedicine", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2/CD3 bifunctional bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Nov 2028", "nct_id": "NCT01833104", "ct_url": "https://clinicaltrials.gov/study/NCT01833104", "ct_title": "Plasticity of the Compassionate Brain", "ct_status": "COMPLETED"}, {"name": "IR-61", "tumor": "CNS - Neuroblastoma", "company_us": "US West China", "company_eu": "EU West China", "line": "First line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radioconjugate", "stage_raw": "Phase I", "results_date": "Jun 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "EXIomar", "tumor": "CNS - Neuroblastoma", "company_us": "US LINEIS BioTech", "company_eu": "EU LINEIS BioTech", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2/CD3 bifunctional bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Apr 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "I-131-iobenguane", "tumor": "CNS - Neuroblastoma", "company_us": "US Lantheous Holdings", "company_eu": "EU Lantheous Holdings", "line": "First line", "stage": "Phase I", "year": 2020.0, "moa": "Radiopharmaceutical", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radiopharmaceutical", "stage_raw": "Phase I", "results_date": "Nov 2020", "nct_id": "NCT02378428", "ct_url": "https://clinicaltrials.gov/study/NCT02378428", "ct_title": "MIBG Therapy for Patients With MIBG Avid Tumors", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "IR-G1", "tumor": "CNS - Neuroblastoma", "company_us": "US West China", "company_eu": "EU West China", "line": "First line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Radioconjugate", "stage_raw": "Phase I", "results_date": "Jun 2027", "nct_id": "NCT03003754", "ct_url": "https://clinicaltrials.gov/study/NCT03003754", "ct_title": "Supervised Exercise-training in Children With Insulin Resistance or Healthy Metabolic Profile", "ct_status": "COMPLETED"}, {"name": "EXIoman", "tumor": "CNS - Neuroblastoma", "company_us": "US LINEIS BioTech", "company_eu": "EU LINEIS BioTech", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2/CD3 bifunctional bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Apr 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LP-XXI", "tumor": "CNS - Neuroblastoma", "company_us": "US Collaborations Pharmaceuticals", "company_eu": "EU Collaborations Pharmaceuticals", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "TBD", "stage_raw": "Preclinical", "results_date": "Jun 2028", "nct_id": "NCT06292013", "ct_url": "https://clinicaltrials.gov/study/NCT06292013", "ct_title": "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)", "ct_status": "ACTIVE_NOT_RECRUITING"}, {"name": "NRK cells", "tumor": "CNS - Neuroblastoma", "company_us": "US Artinial Pharma", "company_eu": "EU Artinial Pharma", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "NK cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NK cells", "stage_raw": "Phase II", "results_date": "Nov 2027", "nct_id": "NCT01994720", "ct_url": "https://clinicaltrials.gov/study/NCT01994720", "ct_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]", "ct_status": "COMPLETED"}, {"name": "RUMC-8D2-SIRP mab", "tumor": "CNS - Neuroblastoma", "company_us": "US Radioved University", "company_eu": "EU Radioved University", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2-SIRP7 monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Oct 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "LFD03", "tumor": "CNS - Neuroblastoma", "company_us": "US LantheusBioMedicine", "company_eu": "EU LantheusBioMedicine", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Anti-GD2/CD3 bifunctional bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Nov 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "F1801 Combination", "tumor": "CNS - Neuroblastoma", "company_us": "US Guangzhou", "company_eu": "EU Guangzhou", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "NK cells", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "NK cells", "stage_raw": "Preclinical", "results_date": "May 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "KTG81", "tumor": "CNS - Neuroblastoma", "company_us": "US Nanjing CART", "company_eu": "EU Nanjing CART", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "CART GD2", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "CART GD2", "stage_raw": "Preclinical", "results_date": "Nov 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Oturimab", "tumor": "Solid tumors", "company_us": "US Pfizer", "company_eu": "EU Pfizer", "line": "Second line", "stage": "Phase I", "year": 2023.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "C-MET, ALK ROS1 inhibitor", "stage_raw": "Phase I", "results_date": "Jan 2023", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Travorin Combination", "tumor": "Solid tumors", "company_us": "US Modulis Pharmaceuticals", "company_eu": "EU Modulis Pharmaceuticals", "line": "Second line", "stage": "Phase II", "year": 2024.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Alkylating agent", "stage_raw": "Phase II", "results_date": "Feb 2024", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "MB-CART-GD2.16", "tumor": "Solid tumors", "company_us": "US Mablyomix Biotherapeutics", "company_eu": "EU Mablyomix Biotherapeutics", "line": "Third line", "stage": "Phase I", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "CART GD2:IL18", "stage_raw": "Phase I", "results_date": "Jul 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "Mytri-PNAMI", "tumor": "Solid tumors", "company_us": "US Myro Therapeutics", "company_eu": "EU Myro Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-PD-AM p53 bispecific monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Nov 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "CTAKD34-FRO Combination", "tumor": "Solid tumors", "company_us": "US Children's Hospital", "company_eu": "EU Children's Hospital", "line": "Preclinical", "stage": "Preclinical", "year": 2027.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "Anti-ALK ADC monoclonal antibody", "stage_raw": "Preclinical", "results_date": "Sep 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "NRSK-4912", "tumor": "Solid tumors", "company_us": "US Norie Therapeutics", "company_eu": "EU Norie Therapeutics", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "Other", "tumor_raw": "Solid tumors", "moa_raw": "AURKA degrader", "stage_raw": "Preclinical", "results_date": "Apr 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "HCK63", "tumor": "Other", "company_us": "US Immunoadsitive Cell", "company_eu": "EU Immunoadsitive Cell", "line": "Preclinical", "stage": "Preclinical", "year": 2028.0, "moa": "CART GD2", "tumor_raw": "CNS - GBM", "moa_raw": "CART GD2", "stage_raw": "Preclinical", "results_date": "Dec 2028", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "RR-1664", "tumor": "CNS - Neuroblastoma", "company_us": "US XenoTherapeutics", "company_eu": "EU XenoTherapeutics", "line": "Second line", "stage": "Phase II", "year": 2027.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "PLK4 inhibitor", "stage_raw": "Phase II", "results_date": "Jan 2027", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}, {"name": "DQL8-TAT", "tumor": "CNS - Neuroblastoma", "company_us": "US NanoPharmaceutical", "company_eu": "EU NanoPharmaceutical", "line": "Preclinical", "stage": "Preclinical", "year": 2026.0, "moa": "Other", "tumor_raw": "CNS - Neuroblastoma", "moa_raw": "Thymopoetin antagonist", "stage_raw": "Preclinical", "results_date": "Jan 2026", "nct_id": "", "ct_url": "", "ct_title": "", "ct_status": ""}];

const STAGE_ORDER = ['Preclinical', 'Phase I', 'Phase II', 'Phase III', 'Phase IV', 'Approved', 'Other'];
const STAGE_COLORS = {
  'Preclinical': '#818cf8', 'Phase I': '#34d399', 'Phase II': '#fbbf24',
  'Phase III': '#fb923c', 'Phase IV': '#c084fc', 'Approved': '#4ade80', 'Other': '#64748b'
};
const PALETTE = ['#38bdf8','#34d399','#fbbf24','#fb923c','#c084fc','#818cf8','#f472b6',
                 '#22d3ee','#a3e635','#e879f9','#f97316','#14b8a6','#f43f5e','#8b5cf6','#06b6d4'];

let filtered = [...RAW_DATA];
let charts = {};
let currentPage = 0;
let pageSize = 15;
let sortCol = 'name', sortDir = 1;

function init() {
  populateFilters();
  setDefaultYearRange();
  applyFilters();
}

function populateFilters() {
  populateSelect('filterTumor', getUnique('tumor'));
  populateSelect('filterStage', STAGE_ORDER.filter(s => RAW_DATA.some(d => d.stage === s)));
  populateSelect('filterLine', getUnique('line'));
  populateSelect('filterMOA', getUnique('moa'));
  const years = [...new Set(RAW_DATA.map(d => d.year).filter(Boolean))].sort();
  const yearRanges = [];
  for (let y = Math.min(...years); y <= Math.max(...years); y += 5) {
    yearRanges.push(y + '-' + Math.min(y+4, Math.max(...years)));
  }
  populateSelect('filterYear', yearRanges);
  document.getElementById('filterStatus').addEventListener('change', applyFilters);
  document.getElementById('filterCountry').addEventListener('change', applyFilters);
  document.getElementById('filterCTgov').addEventListener('change', applyFilters);
}

function populateSelect(id, values) {
  const el = document.getElementById(id);
  values.forEach(v => {
    const opt = document.createElement('option');
    opt.value = v; opt.textContent = v;
    el.appendChild(opt);
  });
  el.addEventListener('change', applyFilters);
}

function getUnique(field) {
  return [...new Set(RAW_DATA.map(d => d[field]).filter(Boolean))].sort();
}

function applyFilters() {
  const tumor = document.getElementById('filterTumor').value;
  const stage = document.getElementById('filterStage').value;
  const line = document.getElementById('filterLine').value;
  const moa = document.getElementById('filterMOA').value;
  const yearRange = document.getElementById('filterYear').value;
  const status = document.getElementById('filterStatus').value;
  const country = document.getElementById('filterCountry').value;
  const ctgov = document.getElementById('filterCTgov').value;

  const ACTIVE_STAGES = ['Preclinical', 'Phase I', 'Phase II', 'Phase III', 'Phase IV'];

  filtered = RAW_DATA.filter(d => {
    if (tumor && d.tumor !== tumor) return false;
    if (stage && d.stage !== stage) return false;
    if (line && d.line !== line) return false;
    if (moa && d.moa !== moa) return false;
    if (yearRange) {
      const [y1, y2] = yearRange.split('-').map(Number);
      if (!d.year || d.year < y1 || d.year > y2) return false;
    }
    if (status === 'active' && !ACTIVE_STAGES.includes(d.stage)) return false;
    if (status === 'approved' && d.stage !== 'Approved') return false;
    if (country === 'us' && !d.company_us.toLowerCase().includes('us')) return false;
    if (ctgov === 'yes' && !d.nct_id) return false;
    return true;
  });

  updateStats();
  updateCharts();
  currentPage = 0;
  updateTable();
}

function resetFilters() {
  ['filterTumor','filterStage','filterLine','filterMOA','filterYear'].forEach(id => {
    document.getElementById(id).value = '';
  });
  document.getElementById('filterStatus').value = 'active';
  document.getElementById('filterCountry').value = 'us';
  document.getElementById('filterCTgov').value = 'yes';
  setDefaultYearRange();
  applyFilters();
}

function setDefaultYearRange() {
  const sel = document.getElementById('filterYear');
  for (let i = 0; i < sel.options.length; i++) {
    if (sel.options[i].value.startsWith('2024')) {
      sel.value = sel.options[i].value;
      return;
    }
  }
}

function updateStats() {
  document.getElementById('totalCount').textContent = filtered.length;
  document.getElementById('statDrugs').textContent = new Set(filtered.map(d=>d.name)).size;
  document.getElementById('statTumors').textContent = new Set(filtered.map(d=>d.tumor)).size;
  document.getElementById('statCompanies').textContent = new Set(filtered.map(d=>d.company_us)).size;
  document.getElementById('statApproved').textContent = filtered.filter(d=>d.stage==='Approved').length;
}

function countBy(arr, field) {
  const counts = {};
  arr.forEach(d => { counts[d[field]] = (counts[d[field]] || 0) + 1; });
  return counts;
}

function updateCharts() {
  updateStageChart();
  updateTumorChart();
  updateTimelineChart();
  updateMOAChart();
  updateHeatmapChart();
  updateLineChart();
}

function destroyChart(name) {
  if (charts[name]) { charts[name].destroy(); }
}

function updateStageChart() {
  destroyChart('stage');
  const counts = countBy(filtered, 'stage');
  const labels = STAGE_ORDER.filter(s => counts[s]);
  const data = labels.map(s => counts[s] || 0);
  document.getElementById('stageCount').textContent = filtered.length + ' entries';
  
  charts.stage = new Chart(document.getElementById('stageChart'), {
    type: 'doughnut',
    data: {
      labels,
      datasets: [{ data, backgroundColor: labels.map(s => STAGE_COLORS[s]), borderWidth: 0, hoverOffset: 8 }]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: {
        legend: { position: 'right', labels: { color: '#94a3b8', font: { size: 12 }, padding: 12 } },
        tooltip: {
          callbacks: { label: ctx => ctx.label + ': ' + ctx.raw + ' (' + (ctx.raw/filtered.length*100).toFixed(1) + '%)' }
        }
      }
    }
  });
}

function updateTumorChart() {
  destroyChart('tumor');
  const counts = countBy(filtered, 'tumor');
  const sorted = Object.entries(counts).sort((a,b) => b[1]-a[1]);
  const labels = sorted.map(s => s[0]);
  const data = sorted.map(s => s[1]);
  document.getElementById('tumorCount').textContent = labels.length + ' types';

  charts.tumor = new Chart(document.getElementById('tumorChart'), {
    type: 'bar',
    data: {
      labels,
      datasets: [{ data, backgroundColor: PALETTE.slice(0, labels.length).concat(Array(Math.max(0,labels.length-PALETTE.length)).fill('#475569')), borderRadius: 4 }]
    },
    options: {
      responsive: true, maintainAspectRatio: false, indexAxis: 'y',
      plugins: { legend: { display: false } },
      scales: {
        x: { ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } },
        y: { ticks: { color: '#cbd5e1', font: { size: 11 } }, grid: { display: false } }
      }
    }
  });
}

function updateTimelineChart() {
  destroyChart('timeline');
  const yearData = {};
  filtered.forEach(d => {
    if (!d.year) return;
    const y = Math.floor(d.year);
    if (!yearData[y]) yearData[y] = {};
    yearData[y][d.stage] = (yearData[y][d.stage] || 0) + 1;
  });
  const years = Object.keys(yearData).sort();
  const stages = STAGE_ORDER.filter(s => filtered.some(d => d.stage === s));
  
  charts.timeline = new Chart(document.getElementById('timelineChart'), {
    type: 'bar',
    data: {
      labels: years,
      datasets: stages.map(s => ({
        label: s,
        data: years.map(y => yearData[y]?.[s] || 0),
        backgroundColor: STAGE_COLORS[s],
        borderRadius: 2
      }))
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8', font: { size: 11 } } } },
      scales: {
        x: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } },
        y: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } }
      }
    }
  });
}

function updateMOAChart() {
  destroyChart('moa');
  const counts = countBy(filtered, 'moa');
  delete counts['Other'];
  const sorted = Object.entries(counts).sort((a,b) => b[1]-a[1]).slice(0, 15);
  
  charts.moa = new Chart(document.getElementById('moaChart'), {
    type: 'bar',
    data: {
      labels: sorted.map(s => s[0]),
      datasets: [{ data: sorted.map(s => s[1]), backgroundColor: PALETTE, borderRadius: 4 }]
    },
    options: {
      responsive: true, maintainAspectRatio: false, indexAxis: 'y',
      plugins: { legend: { display: false } },
      scales: {
        x: { ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } },
        y: { ticks: { color: '#cbd5e1', font: { size: 10 } }, grid: { display: false } }
      }
    }
  });
}

function updateHeatmapChart() {
  destroyChart('heatmap');
  const tumors = [...new Set(filtered.map(d => d.tumor))].sort();
  const stages = STAGE_ORDER.filter(s => filtered.some(d => d.stage === s));
  
  const matrix = {};
  filtered.forEach(d => {
    const key = d.tumor + '|' + d.stage;
    matrix[key] = (matrix[key] || 0) + 1;
  });

  charts.heatmap = new Chart(document.getElementById('heatmapChart'), {
    type: 'bar',
    data: {
      labels: tumors,
      datasets: stages.map(s => ({
        label: s,
        data: tumors.map(t => matrix[t + '|' + s] || 0),
        backgroundColor: STAGE_COLORS[s],
        borderRadius: 2
      }))
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8', font: { size: 11 } } } },
      scales: {
        x: { stacked: true, ticks: { color: '#94a3b8', font: { size: 10 }, maxRotation: 45 }, grid: { display: false } },
        y: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } }
      }
    }
  });
}

function updateLineChart() {
  destroyChart('line');
  const counts = countBy(filtered, 'line');
  const sorted = Object.entries(counts).sort((a,b) => b[1]-a[1]);
  
  charts.line = new Chart(document.getElementById('lineChart'), {
    type: 'polarArea',
    data: {
      labels: sorted.map(s => s[0]),
      datasets: [{ data: sorted.map(s => s[1]), backgroundColor: PALETTE.map(c => c + '99') }]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { position: 'right', labels: { color: '#94a3b8', font: { size: 11 }, padding: 8 } } },
      scales: { r: { ticks: { color: '#94a3b8', backdropColor: 'transparent' }, grid: { color: '#334155' } } }
    }
  });
}

function updateTable() {
  const sorted = [...filtered].sort((a,b) => {
    const av = a[sortCol] || '', bv = b[sortCol] || '';
    return (av < bv ? -1 : av > bv ? 1 : 0) * sortDir;
  });
  const start = currentPage * pageSize;
  const page = sorted.slice(start, start + pageSize);
  const tbody = document.getElementById('tableBody');
  
  tbody.innerHTML = page.map(d => {
    const sc = d.stage.replace(/\s+/g, '-');
    let ctLink = '';
    if (d.nct_id) {
      const safeTitle = (d.ct_title || '').replace(/"/g, '&quot;');
      ctLink = '<a href="' + d.ct_url + '" target="_blank" rel="noopener" style="color:#4ade80;text-decoration:none;font-weight:600;" title="' + safeTitle + ' (' + d.ct_status + ')">' + d.nct_id + '</a>';
    } else {
      const ctQuery = encodeURIComponent(d.name);
      ctLink = '<a href="https://clinicaltrials.gov/search?term=' + ctQuery + '" target="_blank" rel="noopener" style="color:#94a3b8;text-decoration:none;" title="Search on CT.gov">search</a>';
    }
    return '<tr>' +
      '<td title="' + d.name + '">' + d.name + '</td>' +
      '<td title="' + d.tumor_raw + '">' + d.tumor_raw + '</td>' +
      '<td><span class="stage-badge stage-' + sc + '">' + d.stage + '</span></td>' +
      '<td>' + d.line + '</td>' +
      '<td title="' + d.moa_raw + '">' + d.moa_raw + '</td>' +
      '<td title="' + d.company_us + '">' + d.company_us + '</td>' +
      '<td>' + d.results_date + '</td>' +
      '<td>' + ctLink + '</td></tr>';
  }).join('');

  const totalPages = Math.ceil(filtered.length / pageSize);
  document.getElementById('pageInfo').textContent = 'Page ' + (currentPage+1) + ' of ' + totalPages + ' (' + filtered.length + ' records)';
  document.getElementById('tableCount').textContent = filtered.length + ' records';
  document.getElementById('prevBtn').disabled = currentPage === 0;
  document.getElementById('nextBtn').disabled = currentPage >= totalPages - 1;
}

function changePage(dir) {
  currentPage += dir;
  updateTable();
}

function sortTable(col) {
  if (sortCol === col) sortDir *= -1;
  else { sortCol = col; sortDir = 1; }
  currentPage = 0;
  updateTable();
}

// === TAB SWITCHING ===
function switchTab(tab) {
  document.querySelectorAll('.tab-btn').forEach(b => b.classList.remove('active'));
  document.querySelectorAll('.tab-content').forEach(t => t.classList.remove('active'));
  document.getElementById('tab-' + tab).classList.add('active');
  document.querySelector('[onclick="switchTab(\'' + tab + '\')"]').classList.add('active');
  if (tab === 'analytics' && !window._analyticsRendered) {
    renderAnalytics();
    window._analyticsRendered = true;
  }
}

// === ANALYTICS CHARTS ===
let aCharts = {};
function destroyAChart(name) { if (aCharts[name]) aCharts[name].destroy(); }

function renderAnalytics() {
  const data = RAW_DATA;
  const hasNct = d => d.nct_id && d.nct_id.startsWith('NCT');
  const found = data.filter(hasNct);
  const notFound = data.filter(d => !hasNct(d));

  document.getElementById('aTotal').textContent = data.length;
  document.getElementById('aFound').textContent = found.length;
  document.getElementById('aNotFound').textContent = notFound.length;
  document.getElementById('aPct').textContent = (found.length / data.length * 100).toFixed(1) + '%';

  // Colors
  const GREEN = '#4ade80', RED = '#f87171', BLUE = '#38bdf8', GRAY = '#475569';

  // 1. STAGE CHART - grouped bar
  destroyAChart('stage');
  const stageOrder = ['Preclinical', 'Phase I', 'Phase II', 'Phase III', 'Phase IV', 'Approved', 'Other'];
  const stageLabels = stageOrder.filter(s => data.some(d => d.stage === s));
  const stageFound = stageLabels.map(s => found.filter(d => d.stage === s).length);
  const stageNotFound = stageLabels.map(s => notFound.filter(d => d.stage === s).length);
  const stagePct = stageLabels.map((s, i) => {
    const t = stageFound[i] + stageNotFound[i];
    return t ? Math.round(stageFound[i] / t * 100) : 0;
  });

  aCharts.stage = new Chart(document.getElementById('aStageChart'), {
    type: 'bar',
    data: {
      labels: stageLabels.map((s, i) => s + ' (' + stagePct[i] + '%)'),
      datasets: [
        { label: 'Found on CT.gov', data: stageFound, backgroundColor: GREEN, borderRadius: 4 },
        { label: 'Not found', data: stageNotFound, backgroundColor: RED + '66', borderRadius: 4 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8' } } },
      scales: {
        x: { stacked: false, ticks: { color: '#cbd5e1', font: { size: 11 } }, grid: { display: false } },
        y: { ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } }
      }
    }
  });

  // 2. CT STATUS DONUT
  destroyAChart('ctStatus');
  const statusCounts = {};
  found.forEach(d => { statusCounts[d.ct_status] = (statusCounts[d.ct_status] || 0) + 1; });
  const statusLabels = Object.keys(statusCounts).sort((a,b) => statusCounts[b] - statusCounts[a]);
  const statusColors = {
    'RECRUITING': '#4ade80', 'ACTIVE_NOT_RECRUITING': '#38bdf8', 'COMPLETED': '#94a3b8',
    'NOT_YET_RECRUITING': '#a78bfa', 'UNKNOWN': '#fbbf24', 'TERMINATED': '#f87171',
    'WITHDRAWN': '#fb923c', 'AVAILABLE': '#22d3ee', 'NO_LONGER_AVAILABLE': '#64748b'
  };

  aCharts.ctStatus = new Chart(document.getElementById('aCtStatusChart'), {
    type: 'doughnut',
    data: {
      labels: statusLabels,
      datasets: [{ data: statusLabels.map(s => statusCounts[s]), backgroundColor: statusLabels.map(s => statusColors[s] || GRAY), borderWidth: 0, hoverOffset: 8 }]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { position: 'right', labels: { color: '#94a3b8', font: { size: 11 }, padding: 8 } } }
    }
  });

  // 3. TUMOR CHART - horizontal bar with %
  destroyAChart('tumor');
  const tumorCounts = {};
  data.forEach(d => {
    if (!tumorCounts[d.tumor]) tumorCounts[d.tumor] = { found: 0, total: 0 };
    tumorCounts[d.tumor].total++;
    if (hasNct(d)) tumorCounts[d.tumor].found++;
  });
  const tumorSorted = Object.entries(tumorCounts).filter(e => e[1].total >= 3).sort((a,b) => b[1].total - a[1].total);
  const tumorLabels2 = tumorSorted.map(e => e[0] + ' (' + Math.round(e[1].found/e[1].total*100) + '%)');

  aCharts.tumor = new Chart(document.getElementById('aTumorChart'), {
    type: 'bar',
    data: {
      labels: tumorLabels2,
      datasets: [
        { label: 'Found', data: tumorSorted.map(e => e[1].found), backgroundColor: GREEN, borderRadius: 3 },
        { label: 'Not found', data: tumorSorted.map(e => e[1].total - e[1].found), backgroundColor: RED + '66', borderRadius: 3 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false, indexAxis: 'y',
      plugins: { legend: { labels: { color: '#94a3b8' } } },
      scales: {
        x: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } },
        y: { stacked: true, ticks: { color: '#cbd5e1', font: { size: 11 } }, grid: { display: false } }
      }
    }
  });

  // 4. YEAR CHART - line + bar combo
  destroyAChart('year');
  const yearCounts = {};
  data.forEach(d => {
    if (!d.year) return;
    const y = Math.floor(d.year);
    if (!yearCounts[y]) yearCounts[y] = { found: 0, total: 0 };
    yearCounts[y].total++;
    if (hasNct(d)) yearCounts[y].found++;
  });
  const years = Object.keys(yearCounts).sort();

  aCharts.year = new Chart(document.getElementById('aYearChart'), {
    type: 'bar',
    data: {
      labels: years,
      datasets: [
        { label: 'Found', data: years.map(y => yearCounts[y].found), backgroundColor: GREEN, borderRadius: 3, order: 2 },
        { label: 'Not found', data: years.map(y => yearCounts[y].total - yearCounts[y].found), backgroundColor: RED + '66', borderRadius: 3, order: 3 },
        { label: 'Match %', data: years.map(y => Math.round(yearCounts[y].found / yearCounts[y].total * 100)), type: 'line', borderColor: BLUE, backgroundColor: BLUE + '33', yAxisID: 'pct', tension: 0.3, pointRadius: 4, pointBackgroundColor: BLUE, order: 1 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8' } } },
      scales: {
        x: { stacked: true, ticks: { color: '#94a3b8' }, grid: { display: false } },
        y: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' }, title: { display: true, text: 'Count', color: '#64748b' } },
        pct: { position: 'right', min: 0, max: 100, ticks: { color: BLUE, callback: v => v + '%' }, grid: { display: false }, title: { display: true, text: 'Match %', color: BLUE } }
      }
    }
  });

  // 5. MOA CHART
  destroyAChart('moa');
  const moaCounts = {};
  data.forEach(d => {
    const m = d.moa_raw || 'Unknown';
    if (!moaCounts[m]) moaCounts[m] = { found: 0, total: 0 };
    moaCounts[m].total++;
    if (hasNct(d)) moaCounts[m].found++;
  });
  const moaSorted = Object.entries(moaCounts).filter(e => e[1].total >= 5).sort((a,b) => (b[1].found/b[1].total) - (a[1].found/a[1].total)).slice(0, 15);

  aCharts.moa = new Chart(document.getElementById('aMoaChart'), {
    type: 'bar',
    data: {
      labels: moaSorted.map(e => e[0] + ' (' + Math.round(e[1].found/e[1].total*100) + '%)'),
      datasets: [
        { label: 'Found', data: moaSorted.map(e => e[1].found), backgroundColor: GREEN, borderRadius: 3 },
        { label: 'Not found', data: moaSorted.map(e => e[1].total - e[1].found), backgroundColor: RED + '66', borderRadius: 3 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false, indexAxis: 'y',
      plugins: { legend: { labels: { color: '#94a3b8' } } },
      scales: {
        x: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } },
        y: { stacked: true, ticks: { color: '#cbd5e1', font: { size: 10 } }, grid: { display: false } }
      }
    }
  });

  // 6. LINE OF TREATMENT
  destroyAChart('line');
  const lineCounts = {};
  data.forEach(d => {
    if (!lineCounts[d.line]) lineCounts[d.line] = { found: 0, total: 0 };
    lineCounts[d.line].total++;
    if (hasNct(d)) lineCounts[d.line].found++;
  });
  const lineSorted = Object.entries(lineCounts).sort((a,b) => b[1].total - a[1].total);

  aCharts.line = new Chart(document.getElementById('aLineChart'), {
    type: 'bar',
    data: {
      labels: lineSorted.map(e => e[0] + ' (' + Math.round(e[1].found/e[1].total*100) + '%)'),
      datasets: [
        { label: 'Found', data: lineSorted.map(e => e[1].found), backgroundColor: GREEN, borderRadius: 4 },
        { label: 'Not found', data: lineSorted.map(e => e[1].total - e[1].found), backgroundColor: RED + '66', borderRadius: 4 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8' } } },
      scales: {
        x: { stacked: true, ticks: { color: '#cbd5e1', font: { size: 10 }, maxRotation: 45 }, grid: { display: false } },
        y: { stacked: true, ticks: { color: '#94a3b8' }, grid: { color: '#1e293b' } }
      }
    }
  });

  // 7. NAMING PATTERNS - grouped bar
  destroyAChart('naming');
  function hasDigits(n) { return /\d/.test(n || ''); }
  function hasSpecial(n) { return /[\/\*\+\-]/.test(n || ''); }
  function isINN(n) { return /(mab|nib|lib|tin|cel|rib|stat|tide|pib|zole)$/i.test((n||'').trim()); }
  function hasCombo(n) { return /combination/i.test(n || ''); }

  const patterns = ['Has digits', 'Has special chars', 'INN name (-mab,-nib...)', 'Combination'];
  const patternFns = [hasDigits, hasSpecial, isINN, hasCombo];
  const patFoundPct = patternFns.map(fn => Math.round(found.filter(d => fn(d.name)).length / found.length * 100));
  const patNotPct = patternFns.map(fn => Math.round(notFound.filter(d => fn(d.name)).length / notFound.length * 100));

  aCharts.naming = new Chart(document.getElementById('aNamingChart'), {
    type: 'bar',
    data: {
      labels: patterns,
      datasets: [
        { label: 'Found on CT.gov (%)', data: patFoundPct, backgroundColor: GREEN, borderRadius: 4 },
        { label: 'Not found (%)', data: patNotPct, backgroundColor: RED + '66', borderRadius: 4 }
      ]
    },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: { legend: { labels: { color: '#94a3b8' } }, tooltip: { callbacks: { label: ctx => ctx.dataset.label + ': ' + ctx.raw + '%' } } },
      scales: {
        x: { ticks: { color: '#cbd5e1' }, grid: { display: false } },
        y: { ticks: { color: '#94a3b8', callback: v => v + '%' }, grid: { color: '#1e293b' }, max: 50 }
      }
    }
  });

  // 8. HEATMAP - Stage x top tumors
  destroyAChart('heat');
  const topTumors = ['Ewing Sarcoma', 'CNS - Neuroblastoma', 'Solid tumors', 'Soft tissue sarcoma (STD)', 'Soft tissue sarcoma (STS)'];
  const heatStages = ['Preclinical', 'Phase I', 'Phase II', 'Phase III', 'Phase IV', 'Approved'];
  const heatData = [];
  topTumors.forEach(tumor => {
    heatStages.forEach(stage => {
      const sub = data.filter(d => d.tumor === tumor && d.stage === stage);
      if (sub.length > 0) {
        const pct = Math.round(sub.filter(hasNct).length / sub.length * 100);
        heatData.push({ tumor, stage, pct, total: sub.length });
      }
    });
  });

  const heatLabels = topTumors;
  const heatDatasets = heatStages.map(stage => ({
    label: stage,
    data: topTumors.map(tumor => {
      const cell = heatData.find(h => h.tumor === tumor && h.stage === stage);
      return cell ? cell.pct : null;
    }),
    backgroundColor: topTumors.map(tumor => {
      const cell = heatData.find(h => h.tumor === tumor && h.stage === stage);
      if (!cell) return 'transparent';
      const p = cell.pct;
      if (p >= 60) return '#4ade8099';
      if (p >= 30) return '#fbbf2499';
      return '#f8717199';
    }),
    borderRadius: 3
  }));

  aCharts.heat = new Chart(document.getElementById('aHeatChart'), {
    type: 'bar',
    data: { labels: heatLabels, datasets: heatDatasets },
    options: {
      responsive: true, maintainAspectRatio: false,
      plugins: {
        legend: { labels: { color: '#94a3b8', font: { size: 10 } } },
        tooltip: { callbacks: { label: ctx => ctx.dataset.label + ': ' + (ctx.raw !== null ? ctx.raw + '%' : 'N/A') } }
      },
      scales: {
        x: { ticks: { color: '#cbd5e1', font: { size: 10 } }, grid: { display: false } },
        y: { ticks: { color: '#94a3b8', callback: v => v + '%' }, grid: { color: '#1e293b' }, max: 100, title: { display: true, text: '% linked to CT.gov', color: '#64748b' } }
      }
    }
  });

}


init();
</script>
</body>
</html>